full list rate price target
earn chang report pleas see
tabl page
barclay bank plc and/or affili provid invest bank servic bravo
bidco limit nyse offer btg lse btg
rate price target estim applic boston scientif corp nyse
previous issu firm research depart temporarili suspend
due potenti transact
welcom med-tech prep book barclay healthcar confer edit
book contain plethora inform cover med-tech compani
present healthcar confer report find
snapshot compani bull bear thesi upcom event possibl
questions/top manag team along background inform hope
find help resourc prepar upcom meet
sentiment med-tech sector
med-tech outperform market sector pace in-
line thu far march hc equip suppli index
versu small mid cap med-tech stock
posit year modestli under-perform respect indic
fundament across sector remain favor view valuat becom
concern hesit point among investor dont disagre sector
trade toward higher end long-term averag
big pictur topic wed focu
think investor focu whether thing good get med-tech
sale growth rate acceler recent year owe solid underli demand
new product support favor fda environ price remain
headwind stabl modest would ask manag team
sustain top line growth abil drive margin
expans well tax reform reduc corpor effect tax rate perhap
importantli provid increas flexibl use cash wed focu
capit deploy particularli avenu growth mani
remain posit med-tech concern valuat
view fundament remain posit sector expect compani
see stabl slightli improv sale growth rate leverag bottom line pe
valuat high rel basi believ sustain
think expans opportun may limit
invest view unchang
updat model reflect recent well latest
think compani end market also modestli rais pt
ascrib higher pe high growth compani see tabl
page
barclay capit inc and/or one affili seek busi
compani cover research report result investor awar
firm may conflict interest could affect object report investor
consid report singl factor make invest decis
summari rate price target earn chang report chang shown bold
co
barclay research share price target price shown primari list currenc ep estim shown report currenc
current fiscal year estim barclay research fiscal year estim barclay research
valuat methodolog risk
valuat methodolog set price target primarili reli forward price-to-earnings methodolog believ stock
maintain premium multipl given top line bottom line growth prospect pt appli multipl ep
risk may imped achiev barclay research valuat price abbott signific exposur
emerg market given fx rate could pressur ep new product central posit view approv adopt new product
therefor anoth risk risk includ signific reimburs action medic devic product recal fda warn letter
govern regulatori action
valuat methodolog set price target primarili reli forward price-to-earnings methodolog price target appli
price-to-earnings multipl calendar ep
risk may imped achiev barclay research valuat price upsid new product drive acceler
sale ep growth downsid less favor trend hospit capital-expenditure slower uptak new product strengthen us dollar higher
tax rate risk includ signific reimburs chang fda product approv time competit pressur fda
valuat methodolog set price target primarili reli forward price-to-earnings methodolog price target appli pe
multipl ep estim
risk may imped achiev barclay research valuat price fx rate recent acquisit could
pressur earn growth competit pressur particularli area knee competitor launch compet robotic-assist
system could impact growth outlook sentiment toward stock time ultim receipt new product approv could
affect outlook risk includ signific chang reimburs potenti dilut associ acquisit product failur
fda govern action
current state affair med-tech
med-tech sector modestli under-perform broader indic
med-tech outperform market pace in-lin thu far
march hc equip suppli index
slightli ahead small mid cap med-tech stock posit
year modestli under-perform respect indic
 perform econom sector
 healthcar perform sub-industri
note healthcar includ facil includ
fundament favor rel valuat much
fundament across sector remain favor valuat becom
concern hesit point among investor dont disagre sector trade
histor averag absolut rel basi see figur
absolut rel pe ntm ep estim
composit includ ew well guidant biomet covidien bard st jude medic trade
welcom med-tech prep book barclay healthcar
book contain plethora inform cover med-tech compani
present healthcar confer report find snapshot
compani bull bear thesi upcom event possibl questions/top
manag team along background inform hope find
help resourc prepar upcom meet
big pictur topic wed focu manag team
sustain growth
think investor focu whether thing good get
med-tech sale growth rate acceler recent year owe solid underli
demand new product support favor fda environ continu
see gener favor environ go forward unit state european medic
devic regul becom bit difficult costli would focu
compani product pipelin abil sustain ideal acceler sale growth
price remain headwind across med-tech sector stabl
modest price hot topic biopharmaceut landscap
manag would discuss view price outlook could prompt
chang current price trend would focu reimburs dynam
unit state well global given signific amount sale across
industri deriv intern market
med-tech product typic high gross margin profil sale market support
 cost vari depend individu sub-sector net/net med-tech compani
gener attract oper margin profil past sever year mani
compani expand oper margin manag team continu
point expans opportun ahead would discuss confid achiev
capit deploy expect
 tax reform reduc effect tax rate perhap importantli provid
increas flexibl use cash would focu capit deploy particularli
context avenu growth mani compani
relev medic industri confer
american academi orthoped surgeon aao
latest scienc area orthoped typic major orthoped
manufactur host investor brief confer year compani
snn wright medic
american colleg cardiolog
annual meet nearli profession attende relev
compani technolog cardiolog pharmaceut medic
devic health imag diagnost industri medic devic
compani host event meet year major data
transcathet valv landscap relev ew
abbott
societi american gastrointestin endoscop surgeon sage
meet focus minim invas surgeri includ laparoscop
robot approach typic host investor
brief time-to-tim well
american associ neurolog surgeon aan
symposium advanc wound spring wound heal societi
meet electrophysiologist other focus treat heart
rhythm disord past
host investor brief confer
confer focus intervent cardiovascular medicin
relev intervent cardiolog compani
meet focus mainli pharmaceut therapi also includ
track insulin pump continu glucos monitor
clinic congress focus structur heart diseas topic includ valv
well laa pfl closur therapi
american associ clinic chemistri aacc
meet focus clinic laboratori scienc diagnost
american associ diabet educ aad
european societi cardiolog esc
meet focus varieti topic cardiolog relev
pharmaceut well medic devic
heart failur societi america hfsa
meet focus heart failur includ left ventricular assist devic
american societi radiat oncologist astro
american academi otolaryngology-head neck surgeri aao-hnsf
confer focus otolaryngolog ear nose throat well
head neck surgeri
one largest medic confer intervent cardiolog relev
topic includ transcathet valv laa coronari stent
confer relev major compani cardiolog corpor
typic host form investor meet conjunct
symposium advanc wound fall symposium
american academi ophthalmolog
focus technolog prevent ill readmiss
american colleg surgeon ac
latest vascular intervent
american associ hip knee surgeon aahk
cardiolog meet mainli focus pharmaceut treatment
also includ content relev medic devic diagnost
confer focus transcathet heart valv therapi
meet design vascular surgeon intervent radiologist
intervent cardiologist vascular specialist
radiolog societi north america rsna
quarterli annual ep usd
consensu number refinitiv receiv gmt
price pe perform
abbott spun effect share appreci prospect improv growth abbott announc
divestitur develop market establish pharmaceut busi juli share trade sideway
attribut emerg market concern abbott announc two major acquisitionsaler februari st jude medic
april abbott close acquisit st jude januari share move higher underli growth trend
sale product categori
sale geographi
includ nutrit supplement infant children major brand name segment includ pedialit
prevent dehydr pediasur gener pediatr nutrit similac babi formula
includ adult nutrit product specifi meet varieti nutrit goal brand name rang fit
target product like ea protein bar glucerna patient diabet ensur gener adult
diagnost product includ hospit lab clinic instrument system built monitor gener
health help diagnos treat diseas
categori consist system analyz dna rna physician research use treat diseas
identifi specif therapi
point
lab qualiti diagnost test system design rapid portabl includ handheld blood analyz
platform test target avail
abbott brand gener pharmaceut includ therapeut gastroenterolog women health
cardiovascular pain central nervou system respiratori drug vaccin
product includ pacemak system implant defibril cardiac resynchron devic
divis includ product design correct monitor cardiac arrhythmia product includ ablat
cathet gener cardiac map system confirmrx implant cardiac monitor
product divis design monitor treat heart failur product includ heartmat left ventricl
assist devic cardio mem pulmonari arteri sensor
abbott varieti product line includ stent coronari balloon cathet guidewir imag solut
structur heart product includ devic design repair damag heart valv transcathet solut
product includ mitraclip mitral valv repair portico transcathet aortic valv replac amplatz
occlud surgic heart valv
abbott neuromodul devic includ spinal cord stimul treatment chronic pain disord deep
divis includ full product suit treat patient diabet includ glucos monitor test strip
sensor data manag softwar accessori freestyl brand divis also includ abbott
pediatr rapid barclay medic suppli devic
sale street organ sale growth rate ep in-
line street/our estim mid-point guidanc
abbott expect organ sale growth ep
double-digit mid-point fx repres headwind sale
earn believ guidanc gener line expect ep
rang bracket consensu net/net noth chang posit view
compani stock
addit detail quarter
million except per share data chang sale constant currenc organ basi unless otherwis note
despit difficult comp abbott deliv anoth quarter strong organ
growth sale organ basi led medic devic
full year abbott organ sale growth abbott expect
momentum continu guid organ sale growth
despit difficult comparison
freestyl libr continu growth driver sale quarter
billion year doubl prior year abbott gain user
bring total activ user base billion
mitraclip sale increas y/i faster growth us coapt data
submit fda support expand indic
sale sale growth slightli lighter expect epd sale softer
medic devic growth strong
segment weaker perform vascular
neuromodul
neg fx impact larger anticip
gross margin expect y/i fx weigh
tax rate lower believ abbott reinvest sg higher
sale constant currenc organ basi
gross margin y/i abbott benefit deal synergi well
busi wide emphasi margin improv see advers fx impact
adjust tax rate lower expect
adjust ep in-lin street estim
abbott expect organ sale growth littl less organ basi expect establish pharma epd sale growth
mid-singl digit mid-high singl digit emerg market declin market nutrit low-
to-mid singl digit legaci diagnost busi mid-to-high singl digit rapid diagnost expect flat due
tough comp last year flu season medic devic high-singl digit fx expect headwind abbott
expect ep time earn releas street estim
abbott expect organ sale growth reflect expect epd sale growth mid-to-high singl digit
nutrit low-to-mid singl digit legaci diagnost mid-to-high singl digit rapid diagnost low-to-mid
singl digit medic devic high-singl digit fx expect neg impact sale ep guidanc
time earn releas street fx expect neg impact ep
actualsal laboratori management chang barclay medic suppli devic
abbott diversifi compani multipl driver
growth sale growth rate acceler recent year
given product pipelin peer growth
compani significantli de-lev past sever
year financi flexibl addit
sale growth improv may peak level
stori well appreci
manag success appear work given
promot robert ford role
view abbott high-qual growth asset believ compani favor mix
busi product well geograph perspect see medic devic busi
key driver growth go forward believ growth profil warrant premium
american colleg cardiolog meet
soon fda approv freestyl libr
possibl question topic manag
manag view long-term growth profil compani
sustain current sale growth rate key driver
current think manag success given recent appoint robert
ford posit
manag thought capit deploy near intermedi term
manag current think
pro con spin nutrit establish pharmaceut busi
medic devic diagnost franchis would will sell one
see long-term market opportun freestyl libr view
competit landscap near longer term product pipelin diabet
describ competit posit alin expect roll-out
view outlook medic devic key new product
drive revenu growth near longer term
possibl questions/top manag
possibl question manag
confid manag abil deliv forecast
factor could drive downsid upsid number
investor think long-term growth profil compani
sustain believ sale growth rate key driver
top line growth
past three year abbott organ sale growth profil improv
abbott sale abbott sale compar
oper basi abbott sale grew organ basi fairli
well balanc medic devic establish
diagnost nutrit ep increas adjust basi
januari abbott manag team provid initi guidanc abbott expect
organ sale growth reflect epd sale growth mid-to-high singl
digit nutrit low-to-mid singl digit legaci diagnost mid-to-high
singl digit rapid diagnost low-to-mid singl digit medic devic
high-singl digit fx expect neg impact sale ep
guidanc fx expect neg impact ep
possibl question manag
discuss manag success plan would would make
robert ford suitabl candid ceo posit
octob abbott name robert ford presid chief oper offic prior
past three year mr ford execut vice presid medic devic
respons diabet structur heart cardiovascular
neuromodul busi capac mr ford oversaw integr st jude
medic busi mr ford join abbott within diagnost busi also
held posit within nutrit diabet busi
mile white took ceo posit januari time three
candid gener consid duan burnham potenti successor paul
clark oversaw pharmaceut robert parkinson ran intern mile
white ran diagnost busi howev ultim board director
decid appoint mile white ceo robert parkinson parkinson would
later retir abbott effect januari enter academia briefli
resurfac baxter ceo manag team structur reorgan
parkinson departur abbott anoth richard gonzalez took
posit march decemb
possibl question manag
investor think manag alloc capit near
intermedi term optim leverag level
current thought
would consid spin nutrit establish pharmaceut
busi medic devic diagnost franchis would
will sell one
sinc spin-off brand pharmaceut busi abbott engag
number portfolio manag action alter composit establish
pharmaceut divis epd divestitur establish market busi
purchas pharmaceut veropharm abbott also
significantli alter mix busi mix acquisit st jude medic
medic devic busi aler expand rapid
diagnost februari abbott sold medic optic busi johnson
financ st jude medic aler acquisit abbott issu signific amount
debt total debt reach high approxim billion decemb
cours compani significantli de-lev decemb
abbott total debt approxim billion
respect abbott comment call alway keep ear
ground hasnt seen anyth draw attent doesnt anyth
radar screen think benefici rather continu priorit invest
spend intern build capac freestyl libr expans
alin manag echo comment call januari
possibl question manag
launch freestyl libr progress unit state rel
origin expect
comment recent prescript rate attrit rate
roll-out freestyl libr perform europ major
market rel expect
see long-term market opportun freestyl libr
roll-out freestyl libr europ receiv
expect freestyl libr and/or iter come unit state
view dexcom/verili miniatur continu glucos
monitor program could risk longer term freestyl libr
similar effort underway
abbott diabet busi gener sale million repres total sale
sale oper basi histor abbott sold tradit
blood glucos monitor meter test trip howev begin abbott launch
freestyl libr continu blood glucos monitor system freestyl libr
account half busi today gener billion sale
view freestyl libr potenti multi-billion dollar product abbott
next sever year compani continu grow intern proce
roll-out unit state
freestyl libr cgm system includ handheld reader dispos sensor
worn back upper arm fingerstick calibr requir abbott first
launch freestyl libr system europ abbott receiv fda approv
sensor system septemb sensor system juli
octob abbott receiv ce mark european approv freestyl libr
add option real-tim alarm function lack real-tim alarm view
competit disadvantag rel cgm system market would expect
abbott pursu approv freestyl libr unit state abbott also evalu
use pediatr patient product current approv adult year
freestyl libr system use million peopl diabet
global countri abbott secur partial full reimburs
system countri
cgm system avail market includ
dexcom latest gener cgm system receiv fda approv march
devic provid real-tim glucos inform everi five minut
read period sensor worn day system
requir fingerstick calibr treatment decis made without
confirmatori fingerstick revenu total million
medtron guardian connect cgm commerci launch june
cgm sensor worn day devic also take sensor glucos
read everi hour unlik dexcom abbott freestyl libr guardian
connect cgm system indic adjunct devic complement replac
inform obtain standard blood glucos monitor devic devic also
requir calibr everi hour work get label
eversens cgm includ profession insert implant
sensor place upper arm last month system approv
june glucos data automat sent everi minut mobil app
user smartphon system requir fingerstick calibr intend
complement replac fingerstick blood glucos monitor
look ahead provid look iter technolog
verili work togeth develop miniatur continu glucos monitor
vision make miniatur sensor electron adhes patch believ
collabor verili track deliv next gener cgm platform end
possibl question manag
would describ competit posit alin rel
major manufactur introduc new system
experi date european/intern roll-out
alin famili diagnost system extent alin replac
cycl versu opportun gain share
discuss plan alin roll-out unit state
abbott diagnost divis repres total sale includ core laboratori
system molecular diagnost system point care system rapid diagnost system
product gener sold blood bank hospit commerci lab clinic
physician offic govern agenc altern care test site plasma protein
alin diagnost system integr famili next-gener diagnost system
solut intern market abbott roll alin clinic
chemistri alin immunoassay diagnost alin blood plasma
screen late abbott receiv fda approv alin alin
system await approv critic mass assay execut fulli
roll-out plan manag current expect begin roll instrument
back half alin molecular diagnost approv use europ
expect approv us late collect believ system
launch sustain improv upon abbott mid-single-digit diagnost sale growth
possibl question manag
expect receiv expand indic mitraclip base
coapt data expect see acceler growth thereaft
develop plan mitraclip term next gener clip
may make easier physician clip leaflet
view competit threat edward pascal system
expect current patent litig edward
expect receiv injunct
abbott structur heart franchis today repres approxim sale includ
product mitraclip percutan mitral valv repair system tissu
mechan surgic heart valv amplatz occlud portico transcathet aortic
mitraclip key contributor structur heart sale growth mitraclip sale
approxim million surpass million
mitraclip transcathet mitral valv repair system approv sinc march
europ sinc octob us us approv limit patient
signific symptomat primari degen mitral regurgit septemb
result coapt studi releas show significantli lower rate
hospit heart failur all-caus mortal month compar medic
therapi alon data file fda support expand indic includ
moderate-to-sever sever secondari function mitral regurgit coapt result
doubl tripl address popul abbott estim patient popul
us alon put total address market valu excess billion
edwardss pascal system could repres competit mitraclip pascal system
transcathet mitral valv leaflet repair system includ spacer paddl
clasp mitral valv leaflet edward initi enrol clasp iid us
pivot trial enrol least patient symptomat primari degen
mitral regurgit deem candid mitral valv surgeri patient
select criterion consist current label indic mitraclip pre-
coapt trial random edward pascal abbott mitraclip edward
also evalu patient suitabl pascal separ arm studi
januari abbott file patent litig suit edward claim
pascal system infring multipl abbott patent cover mitraclip system
unit state lawsuit claim pascal infring five abbott patent patent number
patent patent patent
patent patent abbott seek monetari
damag well preliminari perman injunct abbott also file suit
edward unit kingdom germani switzerland
possibl question manag
beyond mitraclip new product within structur heart busi
excit
see potenti growth rate structur heart franchis
next year
expect us approv portico strategi
launch given youll fourth entrant market would will
price aggress
current statu on-going clinic trial tendyn
believ transept deliveri ultim requir commerci success
view cephea valv
current statu amplatz amulet program
abbott structur heart franchis today repres approxim sale includ
product mitraclip percutan mitral valv repair system tissu
mechan surgic heart valv amplatz occlud portico transcathet aortic
valv look ahead number new er product and/or indic expans
could fuel futur growth
abbott acquir portico transcathet aortic valv replac tavr devic
st jude medic acquisit portico valv size receiv ce mark european
approv novemb addit size subsequ approv decemb
septemb
one-year result portico studi real-world analysi present last septemb
year kaplan-mei estim all-caus mortal cardiovascular mortal disabl
stroke rate myocardi infarct respect
paravalvular leakag moder higher patient sever leakag new
pacemak rate pacemak nave patient day year
abbott us pivot trial data expect releas transcathet cardiovascular
therapeut tct confer fall portico trial includ
approxim high risk extrem risk patient random either portico valv
commerci avail valv edward sapien corevalve/evolut abbott
also evalu next-gener flexnav deliveri system addit patient
abbott plan launch portico unit state earli
estim portico valv sale current million rang favor us
clinic trial data us launch would help expand abbott share billion
tendyn mitral valv replac program acquir abbott august
devic evalu treatment symptomat sever mitral regurgit
ce mark trial enrol complet abbott expect launch system earli
europ respect unit state market juli abbott receiv fda
approv begin pivot summit trial evalu tendyn mitral valv
patient mitral regurgit patient studi random ratio
tendyn devic convent mitral valv surgeri primari endpoint
composit endpoint death cardiovascular hospit stroke reoper one
year would anticip trial could take two year enrol put data read-
late approv possibl
abbott also anoth transcathet mitral valv replac program development-
-the cephea valv abbott provid capit secur option purchas cephea
exercis option acquir compani januari cephea
august abbott initi enrol trilumin ce mark trial
clip-bas transcathet tricuspid repair system build mitraclip system
studi evalu symptomat patient site unit state europ
primari endpoint echocardiograph tricuspid regurgit reduct grade
day procedur assess major advers event month
abbott expect complet trial late ce mark european approv late
us pivot trial expect begin abbott estim roughli
million undertr patient eu us make anoth potenti larg market
approv januari us clinic trial amplatz amulet initi
septemb trial random patient either amplatz amulet devic
watchman laa closur devic control group enrol expect
complet earli follow-up complet sometim
late would put potenti fda approv second half estim
left atrial appendag market roughli million size today potenti
grow billion given number patient atrial fibril
possibl question manag
rate expect vascular busi grow next year
given current product competit market
plan differenti surveil dcb market place
feel need add addit product gain greater scale
latest updat percutan heart pump php potenti
timelin market
abbott vascular busi account total compani sale includ xienc
famili drug-elut coronari stent coronari balloon dilat product guidewir
starclos se perclos proglid vessel closur devic supera peripher stent system
carotid stent imag cathet well pressurewir ffr measur system
drug-coat balloon februari abbott announc sign
agreement wherebi abbott obtain exclus world-wide
commerci right surveil drug-coat balloon ce mark european
approv expect around year end surveil current studi
transcend pivot trial enrol trial random patient
receiv either surveil dcb pact admir dcb primari efficaci
endpoint trial primari patenc defin composit freedom restenosi
clinically-driven target lesion revascular tlr month post-index
procedur surmod expect trial enrol run septemb
would put result read-out late potenti approv
addit surveil dcb abbott also receiv option negoti agreement
surmod below-the-kne arterioven av fistula drug-coat balloon product
estim drug-coat balloon market million market categori
leader capabl expand
percutan heart php heartmat php percutan heart pump
design deliv blood flow mean flow stabil
european approv juli support patient undergo high-risk
percutan coronari intervent pci shield ii us pivot trial initi
howev abbott identifi small number clinic event associ pump
stoppag support high risk pci patient clinic commerci use
prompt abbott halt studi european sale abbott recent
restart shielf ii studi market hemodynam support product measur
billion abiom impella lead product sale expect
compani rang million fiscal year-over-year
possibl question manag
chang made within neuromodul commerci
effort order return segment double-digit growth
key product develop area neuromodul
abbott neuromodul busi account total sale includ spinal cord
stimul proclaim elit prodigi mri proclaim drg design dorsal root
ganglion therapi infin deep brain stimul treatment
movement disord past coupl quarter abbott growth slow
singl digit compani lost share
possibl question manag
nutrit busi sustain current level growth
forese busi track longer term
abbott nutrit divis total sale includ pediatr adult nutrit
product brand market abbott includ similac infant formula isomil
nutrit zone perfect bar adult nutrit myoplex adult nutrit advantedg
adult nutrit product gener sold consum well institut
wholesal retail healthcar facil govern agenc
time spin-off nutrit busi consid driver sale
profit growth busi gener sale growth
respect sale growth slow period
respect abbott face headwind intern market china
abbott nutrit busi grew oper fairli balanc growth
pediatr adult sale stronger
perform unit state
possibl question manag
level confid sustain growth mid-to-high
sensit epd market macro econom trend individu
abbott establish pharmaceut divis epd total sale market
extens portfolio brand gener pharmaceut emerg market focu
key market india russia china brazil abbott five broad therapeut area
focu gastroenterolog product women health product cardiovascular
metabol product pain central nervou system product respiratori drug
vaccin brand gener drug gener sold directli wholesal distributor
govern agenc health care facil pharmaci independ retail
epd sale oper basi
margin return data
balanc sheet cash flow mn
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
overweight view share high-
qualiti growth asset believ compani
favor mix busi product
geograph perspect see medic devic
busi key driver growth go forward
believ growth profil warrant premium
upsid case depend sever key factor
approv new product greater traction new
product success integr st jude
aler busi stable-to-improv trend
downsid case driven foreign
exchang rate slowdown emerg market
growth inabl receiv product approv
price pe perform
quarterli annual ep usd
consensu number refinitiv receiv gmt
avano formerli halyard health spun octob follow period post-spin euphoria stock trade lower
quarterli result live expect under-perform larg due continu poor peform ip segment
stock increas earli follow accret corpak acquisit subsequ sold follow minut segment paint
halyard surgic gown neg light stock later rebound follow improv quarterli result announc sale ip
busi novemb share increas dramat follow ip divestitur may supplier constraint key drug
neg impact on-q product sale caus compani lower full year guidanc stock price also move lower
sale product categori
sale geographi
chronic includ digest health feed solut product along respiratori health product design
chronic care patient brand divis includ mic-key enter feed tube kit feed solut
corpak acquisit ballard airway suction system
pain manag two main franchis acut pain product estim account roughli
two-third total pain manag sale estim sale on-q surgic pain pump
busi remaind iv therapi intervent pain solut account remain
one-third sale includ compani coolief system minim invas water-cool radio-frequ
treatment chronic pain avano ad pain manag franchis juli acquisit
coolsystem game readi game readi offer pain manag rehabilit product orthoped
surgeri patient patient sport relat injuri major product includ grpro cold compress
system atx wrap
chronic barclay medic suppli devic
compani strong balanc sheet posit
drug shortag new competit entrant threaten
complet tuck-in acquisit acceler growth
outlook sale on-q repres sale
compani margin expans stori
competit launch cool radiofrequ ablat
continu improv ebitda margin
platform put growth outlook coolief risk
view sale ip posit catalyst believ compani right strategi
redeploy ip proce medic devic growth initi howev believ
risk on-q franchis may pressur earn leav compani short lrp goal
american academi orthoped surgeon aao
spring present public coolief data oa
april heron htrx pdufa data potenti competitor on-q
possibl question topic manag
see compani strategi unfold next sever year might avano
look like year
level confid achiev long rang plan goal issu last june
thought would prefer multipl smaller-s tuck-in
deal larger transform acquisit
latest think shortag bupivacaine/ropivacain potenti impact
on-q sale
opportun see coolief discuss recent result oa need
chang reimburs perspect drive increas usag
coolief system compar medtron accurian platform
possibl questions/top manag
possibl question manag
see core compet greatest strength compani
convers see greatest weak plan
address
see compani strategi unfold next sever year
might avano look like year
thought would prefer multipl
smaller-s tuck-in deal larger transform acquisit
pacira announc acquisit myoscienc consid
formerli halyard health product strategi shift spin-off
divestitur halyard health form spin-off corpor
healthcar busi octob spin-off halyard strategi
stand-alone compani remain focus shift mix toward higher growth
margin medic devic busi surgic infect prevent ip segment
consist struggl price eros input cost volatil offset much
growth come medic devic segment june woodi took
helm halyard focus remain medic devic segment novemb
halyard announc sale ip busi owen minor deal close
april effect june halyard health chang name avano
medic inc sold name halyard health owen minor sole focus
medic devic focu pain manag chronic care
avano sold ip busi total purchas price million net proce
approxim million avano use proce million retir
remain portion senior secur loan manag intend invest remain
proce back busi acquisit organ growth time
deal close manag estim million acquisit capac
focu acquisit leverag exist technolog expand call point
increas address market
first deploy capit juli acquisit coolsystem inc market
game readi game readi total consider million game readi revenu
million result price sale valuat nearli
revenu game readi market-lead provid cold therapi compress
therapi system market primarili orthopaed sport injury-rel end market
avano intend leverag game readi strong orthoped surgeon relationship
continu increas on-q penetr orthoped procedur game readi pro
forma sale total million increas prior year manag
comment februari earn call expect game readi acceler
februari earn call manag provid updat thought
estim acquisit capac million attribut delta
origin estim million deploy capit game readi well
reduc expect ebitda on-q near-term perform expect
reduc compani intend reinvest busi manag also
note pipelin remain robust evalu number potenti deal
rang size would complement exist busi focu remain
around channel pain also enhanc portfolio chronic moreov
manag comment look two type dealscorpak game
readi like deal could accret contribut posit ebitda well good
batch growth deal
decemb avano million cash restrict cash
million debt
march pacira cover announc acquisit myoscienc privat
compani whose main product iovera fda-approv non-opioid treatment allevi
pain cryoanalgesia product receiv clearanc compani
expect eu canada market submiss accord compani
iovera system use destroy tissu surgic procedur appli freez cold
also use produc lesion peripher nervou tissu applic cold
select site block pain also indic relief pain
symptom associ osteoarthr knee day term
acquisit pacira would pay million up-front million potenti
mileston payment know sale competit process know
avano look compani potenti target would view myoscienc
avano wheel hous sinc area pain manag view iovera
system greater threat potenti competit product area pain
manag deal consumm becom part pacira
possibl question manag
key put take investor consid
signific headwind issu on-q expect
investor think long-term growth profil compani
still feel confid long-rang plan
avano issu initi guidanc februari along earn
manag expect total constant currenc revenu growth includ
benefit game readi acquisit thu organ sale growth expect
also expect impact foreign exchang even versu
manag comment expect reinvest million target
cost transform initi back busi compani expect ep
rang
manag comment hope organ sale flattish year-over-
year although could challeng given flu comp de-stock trend on-q
manag expect sale growth improv year strongest
on-q drug suppli improv
believ risk forecast follow earn call fda updat
drug shortag databas updat ropivacain suppli neg prior
updat januari indic pfizer/hospira ropivacain avail
howev februari updat note next deliveri estim recoveri
present decemb
avano laid long-rang plan investor day june
plan illustr figur forecast acceler top-lin growth mid-singl
high-singl digit along improv profit
avano long rang lrp issu june
embed within assumpt improv margin avano cost transform
program avano estim left approxim million dis-synergi
follow ip divestitur repres cost previous alloc across
 ip medic devic segment cost sole alloc remain
medic devic busi avano intend off-set strand cost
million annual save save expect come gener
suppli chain procur save well continu program
zero-bas budget lean manufactur
believ avano may difficulti achiev lrp target previous
note million save target expens reduct
reinvest back busi believ addit invest spend may
requir achiev target high-singl digit revenu growth and/or
on-q pump challeng competit outlook
possibl question manag
latest think shortag bupivacaine/ropivacain
potenti impact
partnership leiter ramp relationship key
feel on-q posit rel pacira exparel
ad outpati reimburs present potenti headwind on-q
view potenti risk may
pose on-q franchis could similar exparel launch
avano on-q pain relief ambulatori pain pump provid pain relief
five day on-q balloon-typ pump fill local anesthet deliv
cathet place near surgic site physician roughli on-q sale
relat orthoped procedur pump also use cardiovascular
cardiothorac urolog gynecolog obstetr gener surgic procedur
pump program infus local anesthet steadi rate model
allow patient control dose level drug use includ ropivacain use
time estim bupivacain pump predominantli use
avano on-q franchis face challeng past sever quarter two
reasonsshortag bupivacain ropivacain well issu pump filler
avano first note drug shortag reason behind slower-than-expect on-q sale
confer call healthcar facil face shortag anesthet agent
one industri largest drug manufactur on-going manufactur
issu legaci hospira facil hospira struggl maintain proper manufactur
receiv numer warn letter hundr product recal last
decad macpherson kansa plant product site bupivacain ropivacain
receiv fda warn letter februari june fda inform pfizer
complet evalu correct action close warn letter
determin violat address also challeng bupivacain
rocki mount nc site
fda drug shortag databas current list ropivacain bupivacain
shortag bupivacain current backord list major manufactur
 freseniu kabi auromed backord shortag expect
continu least june mani present bupivacain sinc fall
suppli avail ropivacain seem improv manufactur
report current avail howev februari fda updat drug shortag
databas latest inform pfizer/hospira note next
avail expect recoveri ropivacain expect decemb
on-q pump either fill pump filler hospit avano initi
challeng suppli perspect two larger pump filler
locat houston disrupt due hurrican fall
earli pharmedium anoth pump filler shut due
find fda audit juli avano announc prefer provid
relationship leiter fda-regist outsourc provid fill on-q
avano also face competit non-opioid product post-op pain relief
today exparel approv fda use treat post-surg pain
drug expect come market one closest approv
potenti approv april also compani work
non-opioid drug altern
exparel bupivacain liposom inject suspens administ surgic site
time surgeri control pain exparel use pacira proprietari depofoam deliveri
technolog encapsul drug without chang molecular structur
releas desir period time exparel commerci launch
unit state april novemb center medicar medicaid
servic final polici provid separ reimburs exparel
administ ambulatori surgic center asc pay exparel
averag sale price asp code went effect januari
favor data publish recent exparel novemb studi
publish on-line journal medic econom conclud use
exparel manag postsurg pain follow tka lead reduct opioid use
length stay total hospit cost compar patient receiv
exparel convers studi publish journal may
cast neg light on-q studi conclud use
continu pain pump case on-q pump follow total knee arthroplasti
tka lead longer length stay well decreas ambul post-operative
heron cover develop use biochronom
drug deliveri technolog extended-releas formul bupivacain
meloxicam design deliv pain relief hour
shown reduc pain compar bupivacain placebo hernia repair
bunionectomi total knee arthroplasti abdominoplasti breast augment
grant track breakthrough therapi design fda compani
submit new drug applic nda fda fda grant pdufa
date april heron anticip launch around mid-year
taiwan liposom co ltd tlc cover develop treatment
post-surg pain manag bioseiz formul ropivacain tlc
bioseiz lipid formul technolog design enabl local sustain releas
fast onset activ pharmaceut
ingredi api tlc submit
investig new drug ind applic fda april recruit
dose patient inguin hernia repair phase i/ii dose-escal trial
us top line data expect first half
impact treatment liposom bupivacain hospit cost length stay discharg statu patient
undergo total knee arthroplasti high-us institut journal medic econom doi
on-q infus pump link increas hospit stay total knee arthroplasti stephen oneil kristoph
possibl question manag
comfort double-digit sale growth profil coolief
big opportun believ coolief knee osteoarthr
discuss current futur reimburs environ
coolief need enabl adopt
coolief system compar medtron accurian platform
avano compet radiofrequ rf ablat segment coolief rf ablat
technolog tradit rf ablat minim invas procedur use thermal
energi heat destroy nerv fiber stop transmiss pain signal brain
coolief differenti standard rf treatment use water-cool
technolog instead heat gener energi use heat limit amount rf energi
abl deliv given time therebi limit effect standard rf
treatment shape lesion use thermal energi also ellipt necessit
probe place parallel target nerv order success ablat nerv
fiber use cool rf technolog allow addit rf energi creat lesion
volum thermal rf lesion shape spheric allow physician
approach target nerv perpendicularli well parallel combin allow
rf proven provid pain relief far month current almost
entir use treat chronic spine pain knee hip pain compris
procedur volum respect avanoss coolief market share leader
estim sale grown compound-annual-growth-rate
coolief receiv fda approv manag chronic osteoarthr oa knee
pain april coolief remain rf ablat treatment approv treatment
chronic moder sever knee pain caus osteoarthr indic expans
knee pain provid increment million patient popul coolief
march avano releas top line result trial compar efficaci
coolief vs hyaluron acid ha trial evalu patient site patient
random receiv coolief singl inject commerci avail ha trial
achiev primari endpoint statist signific improv knee
osteoarthr patient experienc least reduct knee pain month
treatment coolief versu ha arm patient
coolief arm also achiev statist signific improv function
outcom month view outcom favor await full studi
result submit present public peer-review journal
later year note hyaluron acid market roughli billion size though use
trend lower time effect categori
question american academi orthoped surgeon aao
coolief reimburs profil today larg hospit expect institut
separ code cover new procedur rf nerv ablat januari either
acut ambulatori surgic center offic set chronic pain due oa knee
level reimburs associ code remain uncertain improv
reimburs environ could lead meaning uptak procedur treat
osteoarthritis-rel knee pain worth note though could
hesit refer patient orthoped doctor inject drug would like
refer patient elsewher intervent pain manag specialist get
possibl question manag
larg oral care busi signific share loss
quantifi impact distributor purchas time oral
quantifi impact strong flu season
chronic busi gener million revenu includ two sub-
segment respiratori digest respiratori busi
focus support patient ventil specif reduc occurr
tube ballard close suction system oral care solut
avano digest health busi focus enter feed market enter feed
requir patient function gastrointestin gi tract swallow
digest food normal lead malnutrit
margin return data
balanc sheet cash flow mn
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
underweight view sale ip
posit catalyst believ compani
right strategi redeploy ip proce
medic devic growth initi howev
believ risk on-q franchis
may pressur earn leav compani short
lrp goal rate underweight
upsid case could driven greater sale
 lead improv outlook
greater recoveri on-q busi drug
downsid case could driven deceler
sale growth trend inabl achiev cost
save unsuccess intensifi drug
shortag could pressur on-q sale
new pain drug approvals/competit
quarterli annual ep usd
consensu number refinitiv receiv gmt
price pe perform
share struggl due concern around compani bioscienc busi particular recombin factor viii franchis
march baxter announc would spin-off bioscienc busi spin-off baxalta complet juli
octob baxter announc name almeida posit chairman ceo effect januari share
outperfom period driven earn out-performance stock came pressur
owe concern perform medic deliveri busi baxter announc expans share repurchas
program novemb sinc stock appreci
sale product categori
sale geographi
divis includ product patient chronic kidney diseas end-stag renal diseas compani make
product periton dialysi in-hom hemodialysi in-cent well remot patient monitor system
devic design icu patient need organ support includ prismax continu renal replac
therapi crrt patient acut kidney injuri
product includ iv medic infus system drug reconstitut devic baxter infus pump
divis includ baxter pre-mix inject oncolog drug anesthesia specialti pharmaceut
nutrit divis includ parenter intraven nutrit solut pre-matur babi chemotherapi
patient chronic ill patient patient recov surgeri baxter offer premix nutrit
balanc formula provid manag compound technolog meet uniqu patient need
surgic care product design reduc bleed heal tissu prevent adhes procedur
product includ floseal hemostat matrix product part acquisit
recothrom topic thrombin preveleak surgic sealant
baxter categori includ revenu pharmaceut product baxter manufactur behalf
result better-than-expect top well bottom line
view guidanc bit mix appear surfac
oper growth expect though report sale like
consensu estim ep guidanc bracket street consensu
due non-oper factor share repurchas oper margin
like lower expect ep also street net/net
optic may appear good enough disappoint oper
addit detail quarter
million except per share data chang sale constant currenc organ basi unless otherwis note
result beat sale ep guidanc well street expect sale
vs impli sale guidanc street expect ep vs
upper end guidanc rang street estim
pharmaceut sale ahead expect constant
baxter ep guidanc bracket street consensu howev share
repurchas significantli help ep outlook
share count expect y/i
guidanc street expect manag note headwind due
brevibloc cyclo lvp buy-in year ago exit us in-cent hd product
tough comparison due flu
guidanc oper margin expans
expect also mean larger step lrp
sale constant currenc oper basi
gross margin expect consensu
y/i reflect onetim manufactur cost off-set oper
sg sale y/i compani focus busi
transform initi improv oper effici
 sale y/i anniversari mileston
payment continu invest pipelin
oper margin consensu y/i larg
driven oper expans effect busi manag
adjust tax rate y/i
adjust ep street estim
baxter expect report sale declin constant currenc growth oper sale growth approxim
ep expect
baxter expect report sale flat constant currenc sale growth oper ex-fx cyclo growth
constant currenc basi manag expect renal grow medic deliveri grow easier comp
pharmaceut decreas flat adjust cyclophosphamid clinic nutrit grow advanc surgeri grow
acut therapi grow decreas low singl digit oper margin expect expand y/i tax
rate expect dilut averag share expect net/net ep expect
versu releas estim
baxter signific financi flexibl abil
acquir compani enhanc overal growth
baxter medic deliveri busi under-perform
remain skeptic whether compani
achiev target growth
baxter one best manag team healthcar
stock trade premium valuat pe basi less
expens ev/ebitda basi
warn letter remain overhang prevent
compani receiv fda approv relat drug new
drug key part baxter futur growth
achiev long-rang plan target compani
significantli expand margin profil may prove
difficult
recent month market expect reset lower believ
appropri level near-term ep growth significantli aid financi engin share
repurchas believ warrant lower valuat multipl rel other sector
think risk/reward fairli balanc
possibl question topic manag
confid achiev forecast key put take
investor think long-term growth profil compani manag
still confid achiev long-rang plan target
think product pipelin area manag least confid
current think capit alloc
latest updat fda warn letter relat clari baxter ahmedabad
facil potenti risk mitig effort compani could take extent
resolut take longer expect million new product expect lrp
much deriv clari busi
level comfort long-rang plan forecast medic deliveri
growth main driver behind improv perform simpli
easier comparison expect share gain new product launch
confid manag new pump opportun
confid manag growth outlook renal
possibl questions/top manag
possibl question manag
confid achiev forecast key put
take investor consid
investor think long-term growth profil compani
manag still confid achiev long-rang plan target
manag less confid achiev sale
growth target manag cost structur achiev target ep
pipelin product manag confid area
carri greatest risk
may baxter host bi-annu investor meet provid updat long
rang plan lrp outlook period januari baxter reiter lrp
baxter manag estim weight averag market growth rate wamgr
lrp period baxter expect sale growth baxter
expect growth acceler lrp period sale growth averag
period sale growth period growth
expect come new product geograph expans new product expect
account growth billion long-rang plan term new
product sale divis expect contribut million
follow renal medic deliv million new contribut also
expect acut therapi million clinic nutrit million
baxter expect see continu oper margin expans driven cost
reduct importantli product mix specif baxter expect oper
margin reach expand adjust ep
expect expand oper cash flow free cash flow
expect increas billion billion respect summari
lrp illustr figur
possibl question manag
manag current think opportun
investor interpret recent comment investor
present earn call regard acquisit
area adjac manag believ offer greatest
opportun
would manag will acquisit white space
baxter signific capit flexibl baxter gener billion free cash
flow expect gener billion increas billion nearli
billion decemb baxter billion cash equival
billion total debt leas oblig net debt billion
term capit alloc philosophi manag comment start
reinvest busi deliv exceed plan extent increment
idea capit equip standpoint help acceler growth look properli
fund second prioriti fund dividend rais last sever
year goal move pay-out ratio balanc versu
share buy-back manag focu asset attract market
grow baxter growth rate consid return invest capit
import metric want robust return invest capit year
manag believ logic baxter own asset
plug directli sale forc build onto and/or compet baxter
bring tabl allow extract valu uniqu way versu other
compet compani built cost transform note size
never import factor
sinc spin-off baxalta baxter done transact largest
transact acquisit clari inject limit approxim million
net cash clari ad capabl product gener inject medicin
anesthesia analges renal anti-infect critic care varieti
present includ bag vial ampoul march baxter acquir two
hemostat sealant product recomthrom preveleak
up-front payment million subsequ paid million post-clos
recent investor present baxter manag team mention interest
gener inject icu/crit care set advanc surgeri past baxter
manag also talk chronic diseas manag biosimilar critic
baxter ventur arm invest outset medic compani develop tablo
dialysi system tablo design oper tap water real-tim water
purif system dialysi fluid product integr board baxter also
invest compani target infect prevent includ prescient surgic
surgic site infect medic manag includ kitcheck
possibl question manag
latest updat fda warn letter relat clari baxter
ahmedabad facil potenti risk mitig effort
compani could take extent resolut take longer expect
million new product expect lrp much deriv
clari busi
give confid abil grow busi lrp rate
period key new product
drive growth
busi repres approxim total compani sale
busi includ three categori product estim gener inject drug
repres sale inhal anesthesia drug compound
repres remaind
brevibloc togeth estim rang million
two drug expect see gener eros
baxter cyclophosphamid cylco immunosuppress chemotherapi
agent sandoz launch first gener version product novemb sinc
baxter seen sale cyclo declin million peak
million howev pace eros slower expect gener
competit thu far limit baxter initi guidanc call
million sale million though sale end year
total million baxter initi guidanc million
exceed expect end year million may amneal
pharmaceut announc fda approv anda cyclophosphamid though
impact appear quit limit
baxter brevibloc beta blocker sale total approxim million
million baxter benefit competitor issu sale came
higher manag anticip go forward howev baxter like
see eros brevibloc sale face gener version
approv septemb gener manufactur also approv
list therapeut equival fda
baxter broaden gener inject busi juli acquisit clari
inject limit approxim million net cash clari ad capabl
product gener inject medicin anesthesia analges renal anti-
infect critic care varieti present includ bag vial ampoul
baxter origin expect clari contribut million sale though came
short million
long-rang plan baxter expect busi
provid largest million new product contribut expect increas
number molecul number new product
lrp clari signific contributor new product manag expect add
molecul per year period molecul per year
period howev clari receiv warn letter juli regard
violat current good manufactur practic cgmp regul ahmedabad
india facil fda start inspect day baxter acquir compani
violat correct complianc cgmp confirm fda may withhold
approv new applic supplement
baxter also enter exclus strateg partnership gener oncolog inject
scinopharm taiwan februari scinopharm cover activ
pharmaceut ingredi api manufactur term agreement two
parti develop manufactur baxter hold commerci right five
inject drug arrang also provid baxter option partner
scinopharm mani addit inject molecul product expect
launch begin accord baxter time announc brand
sale initi five product total billion
possibl question manag
level comfort long-rang plan forecast medic
deliveri growth
main driver behind improv perform
simpli easier comparison expect share gain new
confid manag new pump opportun
geograph region feel confid abil gain share
baxter medic deliveri busi account total compani sale roughli two-
third busi intraven iv therapi solut remain third
infus system sigma spectrum infus pump iv set market
product oligopoli grow around year
baxter medic deliveri busi disappoint larg due infus
solut busi sale larg volum parenter lvp increas significantli
thank addit volum product mexico help off-set impact
hurrican maria svp side strength busi baxter rais
guidanc constant currenc growth howev lower guidanc
twice busi follow result manag note take
longer expect gain new custom follow improv lvp suppli
suppli constraint continu small volum parenter svp follow releas
result manag reduc expect busi guid declin
low singl digit manag believ lvp stock took place
earlier year initi expect part driven flu inventori level
need work also note take longer expect see
custom return use svp move use iv push administr
drug well competit product end inventori level stabil
match new level demand medic deliveri busi end year
constant currenc manag express busi rebas
long-rang plan period growth goal still achiev
manag expect growth part reflect easier comparison
three main iv solut compani unit state baxter privat
cover braun privat cover freseniu kabi own freseniu se
co cover hassan al-wake also manufactur iv solut mainli outsid
unit state market estim grow year
past five year us market infus solut suppli challeng
particularli area larg volum parenter lvp includ normal salin
dextros fda drug shortag websit note sodium chlorid inject
bag shortag start januari product remain shortag condit qualiti
control problem one reason capac constraint baxter hurrican
maria impact puerto rico facil also caus signific disrupt particularli
small volum parenter svp solut svp solut volum ml less
design reconstitut activ pharmaceut ingredi api administ
intraven baxter svp includ mini-bag mini-bag plu line
help eas constraint fda approv shipment facil outsid
unit state baxter abl sourc product ireland australia mexico brazil
baxter receiv perman approv fda increas shipment larg
volum iv solut mexico baxter also abl realloc addit iv
solut volum select south american manufactur facil expect
action allow complet remedi activ modern product
process certain manufactur facil puerto rico fda also allow
 braun import product foreign facil allow freseniu grifol import
us well
 braun expect significantli increas amount solut avail
baxter infus system busi includ sale drug pump well associ
tube set unit state three main competitor includ icu
medic baxter braun also provid pump signific market
share outsid unit state smith medic smith group cover also
manufactur pump share outsid unit state
busi seen share challeng past baxter use lead
infus pump leader colleagu platform howev colleagu
histori issu recal ultim led compani put consent
decre fda fda-mand recal remov market
baxter requir either swap pump new oneit acquir
sigma spectrum pumpor offer money hospit entiti purchas new one
baxter acquir stake sigma ultim acquir remain
stake baxter alon pump problem then-cardin health
carefus unit part then-hospira part
also pump recal challeng past net/net baxter end lose roughli
half market share time biggest beneficiari
baxter set sight recaptur infus pump market share us global
us baxter receiv fda clearanc may latest-gener spectrum
pump spectrum iq dose iq safeti softwar spectrum iq design
broad rang auto-program workflow featur set well embed on-
integr outsid unit state baxter aim captur share launch evo
iq infus receiv ce mark regulatori approv uk ireland
australia new zealand august commerci launch activ slate
begin baxter also look launch first syring pump evo iq syring
baxter believ critic success emea latin america
baxter work develop new global pump platform bring togeth
technolog area larg volum pump syring pump pain manag devic
integr back end
possibl question manag
level uptick investor expect kayuga launch japan
manag see market opportun theranova
signific manag view point solut
expect timelin launch
baxter renal busi repres total sale third busi
periton dialysi product remain third hemodialysi product
three main form dialysi therapi today hemodialysi hd home
hemodialysi hhd periton dialysi pd new patient annual incid
nearli hd nearli pd leav less place hhd total
popul preval hd pd nearli hhd
hemodialysi hd perform dialysi center freseniu medic
healthcar partner control market term center
hd blood remov bodi set tube run filter
dialyz remov impur return back bodi individu
undergo treatment three time week session four hour long freseniu
lead manufactur hd dialyz player includ baxter nipro medic
asahi kasei nikkiso braun
hemodialysi hhd perform patient home essenti
process hd hhd treatment plan vari often five six time week
session last hour nxstage acquir freseniu sell home
periton dialysi pd differ approach use tube place
abdomin caviti allow dialysi exchang dialysi fluid pd solut
done night use pd cycler machin day
manual exchang typic last minut patient usual go clinic
month baxter lead provid pd freseniu also sell pd solut
system nxstage also develop periton dialysi system
expect reset lower
believ appropri level near-
term ep growth significantli aid financi
engin share repurchas believ
warrant lower valuat multipl rel other
sector think risk/reward fairli
upsid case could driven gener
competit less expect greater
success bring new product market
greater-than-expect improv profit
accret
downsid case could driven greater-
pressur renal med deliveri fx rate
inabl drive pharma sale pharma price
inabl expand margin
margin return data
balanc sheet cash flow mn
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
co quarterli annual ep usd
consensu number refinitiv receiv gmt
price pe perform
share outperform market past five year compani success execut
integr carefus acquisit complet march april
bd announc intent acquir bard billion bd complet acquisit decemb
stock appreci first half though come pressur owe
concern around outlook fiscal stock preform improv follow
releas result issuanc fiscal guidanc novemb
sale duct categori forma
sale geographi forma
venou cathet midlin cathet port access central line peripher insert central cathet picc acut
extens set iv fluid closed-system drug transfer devic hazard drug detect convent safeti
hypoderm syring needl anesthesia needl spinal epidur tray enter syring sharp dispos
busi includ two main franchis includ infus pump dedic dispos
medic suppli manag system
diabet product includ insulin pen needl syring product infus inject
product includ prefil syring self-inject system safeti shield system sold
pharmaceut compani use contain inject pharmaceut product
product collect blood specimen analysi bd vacutain blood collect
molecular diagnost test system autom cultur system rapid diagnost assay women health
screen test brand name includ bd molecular test system bd surepath cervic cancer screen
instrument reagent diagnost system bd fac product line cell analyz sort
cytometri kiestra lab autom system antibodi immunolog reagent fluoresc dye
hernia soft tissu repair biolog graft bioresorb graft biosurgeri surgic product
bdchloraprep surgic infect prevent product thorac abdomin drainag product mueller
surgic laparoscop instrument product
vascular stent self-expand balloon-expand stent graft vascular graft port biopsi chronic dialysi
feed filter endovascular fistula creation devic drainag product
urolog drainag product intermitt cathet urinari fecal manag devic kidney stone
manag devic target temperatur manag
becton pre-announce sale ep in-lin pre-announce
pre-announc consensu estim compar constant currenc growth
balanc perform across three busi unit ep
better expect driven mainli lower tax rate time discret item well
better sale gross margin earli januari bd manag comment
expect ep low bd provid explicit guidanc
street/our expect re-affirmed full year target net/net view
rel unchang continu see bd steadi compound growth stori
see upsid potenti howev concern around expect
leav us bit sidelin rate share equal weight
addit detail quarter
million except per share data chang sale constant currenc organ basi unless otherwis note
deliv compar constant currenc growth due strong infus
capit placement continu market share gain infus pump
pyxi
pharmaceut system due strong demand core product
surgeri due favor comp due hurrican maria within
hernia busi well benefit reintroduct progel
sale ep guidanc street expect ep guidanc
well street prior estim
medic deliveri solut md peripher intervent pi sale
weaker we/street expect management note in-lin
expect md grew fx neutral compar basi due tough
comp pi due tough comp includ termin distribut
agreement management note safeti concern impact drug-coat balloon sale
sale report basi compar
constant currenc basi growth broad-bas intervent
medic life scienc
gross margin y/i expect
model reflect inclus bard continu improv cost synergi
favor mix off-set fx headwind
sg sale y/i reflect bard higher spend profil
partial off-set synergi
 sale y/i bd continu invest innov
oper margin y/i driven gross margin improv
synergi captur fx neg impact oper margin
adjust tax rate y/i guidanc rang
due time discret item
adjust ep includ fx headwind
bd manag expect revenu growth full year guidanc rang larg due tough flu
comp time within pharm system net put take ep expect addit
headwind fx ep growth impact lower revenu growth raw materi divestitur time expens tax
rate expect full year rate
bd continu expect report sale growth constant currenc compar sale growth reflect
bd medic growth lifesci intervent bd reiter ep guidanc
becton well diversifi compani attract busi
mix categori leadership posit price
pressur limit
sustain growth legaci bard busi may
requir invest spend tuck-in
becton high qualiti manag team deliv
gore royalti annual million end august
past commit
repres headwind ep growth
becton outperform financi commit
carefus acquisit could deliv bard
acquisit well synergi could come higher
compani could see revenu synergi well
stock fairli valu given outlook busi
believ bd success integr bard achiev plan synergi though market
alreadi appreci base success integr carefus ep
recalibr think street forecast may still high see upsid near-term
enough warrant chang view rate ew
aug american associ clinic chemistri aacc
possibl question topic manag
investor think long-term growth profil compani
outlook guid top mid-teen ep growth look beyond
bd top line ep growth profil compani
gore royalti run-rat higher acquir bard still feel comfort
grow mid-teen mid-teen goal adjust number exclud
impact gore royalti
could million bard cost synergi prove conserv could greater cost
synergi perhap lower tax rate help off-set gore royalti headwind
compani achiev optim leverag ratio view outlook capit
deploy compani revert aggress strategi look tuck-in
deriv expect bard sale synergi million area
expect deriv synergi level invest need achiev goal
outlook peripher busi view sustain rate
growth busi light current dcb safeti concern addit competitor enter
market abbott launch drug-elut peripher stent
size near- long-term opportun expand diabet busi
insulin patch smart pen strateg outlook diabet
manag see sustain rate medic manag solut
busi go forward past year better-than-market taken share
infus pump medic manag pyxi
would manag will spin divest diagnost system lifesci
possibl questions/top manag
possibl question manag
investor think long-term growth profil compani
outlook guid top mid-teen ep
growth look beyond bd top line
divis feel least confid top-lin growth
deriv expect bard sale synergi million
area expect deriv synergi level
invest need achiev goal
could million bard cost synergi prove conserv
gore royalti run-rat higher acquir bard still feel
comfort grow mid-teen mid-teen goal
adjust number exclud impact gore royalti
prior bard acquisit novemb manag expect
deliv sale ep growth period april
announc bard transact manag updat longer-rang forecast
inclus bard becton manag expect sale growth
annual oper margin expans mid-teen ep growth period
fiscal becton compar currenc sale growth chang revenu
recognit dispens impact hurrican repres headwind
sale acquisit stronger flu season time sale
tailwind thu net/net becton underli sale growth mid-point
long-rang target bd ep grew constant currenc though estim
underli ep growth closer adjust dispens chang impact
divestitur non-bard acquisit
novemb becton dickinson provid initi guidanc fiscal becton
expect compar constant currenc revenu growth adjust
acquisit divestitur portfolio realign divis becton expect compar
constant currenc revenu growth medic life scienc
reflect tougher flu comp intervent report basi sale
expect increas inclus headwind fx becton expect
ep year-over-year report basi reflect
underli growth plu benefit lower tax rate off-set higher
raw materi cost tariff tougher flu comp
divestitur fx
look beyond fiscal becton face difficult comparison royalti
current receiv gore attribut legaci bard busi ceas august
royalti current annual north million howev end august
expect contribut roughli million fiscal estim
repres per share earn headwind becton
manag comment abl mitig impact earn
pay debt therebi reduc interest expens realiz addit revenu cost
synergi bard acquisit
term bard acquisit manag continu feel confid abil
achiev million cost synergi novemb becton manag
quantifi potenti revenu synergi associ bard acquisit
million
possibl question manag
optim leverag structur compani
compani achiev optim leverag ratio view
outlook capit deploy compani revert aggress
strategi look tuck-in deal go forward
transform portfolio past five year becom larger
divers med-tech compani march complet billion
acquisit carefus ad infus pump medic manag
medic suppli portfolio decemb complet
billion acquisit bard ad peripher intervent surgic access urolog
product mix acquisit becton lever complet transact
move rapidli de-lev afterward end decemb becton gross
leverag becton goal reduc debt level
tuck-in acquisit central bard strategi becton state continu
look supplement legaci bard busi tuck-in deal juli becton acquir
tva medic develop minim invas vascular access product use
hemodialysi compani main product everlinq endoavf system endovascular
adjac opportun read-thru other
possibl question manag
reason chose exit bd simplist gener
inject program year ago sinc seem like logic adjac
attract market opportun note read-thru baxter
expand gener inject busi
infus solut distribut agreement freseniu proceed
met expect and/or greater opportun ahead
pro con enter intraven solut market
given leadership infus system today note relev
would consid broaden busi diabet care includ
believ becton manag offer commentari relev compani
insofar enter exit market opportun past year
provid insight opportun challeng respect area
bd announc program call bd simplist compani effort
enter pharmaceut manufactur take advantag signific
opportun gener inject product becton develop program
year prior announc north carolina plant approv fda
subsequ year becton receiv approv seven drug ready-to-
administ pre-filled glass syring howev becton sold busi freseniu
kabi state believ freseniu kabi logic owner given exist capabl
inject note becton acquir carefus thu decis exit may
also relat bandwidth chang strateg direct manag
focu success integr
along sale bd simplist program freseniu kabi becton enter
year suppli distribut agreement freseniu kabi would suppli bd
portfolio intraven solut earli becton note start ship iv
solut custom partnership freseniu believ revenu
associ distribut agreement minim fiscal
us infus solut market domin three providersbaxt icu medic
legaci hospira braun market suppli shortag number
year owe manufactur challeng encount three compani
baxter infus pump offer custom braun offer
pump unit state significantli smaller share market share larger
outsid us note senat letter address ftc chairwoman edith ramirez
date octob report compani attempt tie
contract pump dispos set along solut practic could scrutin
depart justic
possibl question manag
lesson learn carefus deal term cost
revenu synergi appli applic bard
transact make bard similar make differ
bard acquisit integr perform rel initi
expect area perform better wors
confid abil achiev cost synergi million
could see greater synergi similar carefus deal
million
step-down tax rate fiscal reflect tax synergi
associ bard could addit tax rate reduct year
confid abil achiev revenu synergi million
revenu synergi term product
decemb acquir bard billion cash stock
becton state strateg rational deal includ acceler end-to-end medic
manag infect prevent creat new opportun across rang clinic
impact segment leverag bd global capabl creat new opportun
benefit combin compani product portfolio
onset bard deal becton estim million cost synergi
opportun view market expect becton overachiev target similar
carefus deal onset carefus deal becton estim cost synergi
area million though becton subsequ rais forecast achiev cost
synergi run-rat million septemb
deal model forecast provid street becton includ revenu
tax synergi though note possibl quantifi novemb
becton gave initi view potenti revenu synergi indic believ
million achiev revenu synergi expect come three
area expand vascular access portfolio stronger global surgic offer
global scale geograph expans becton also expect tax rate lower fiscal
versu fiscal realiz tax synergi see benefit
geograph mix
peripher intervent opportun risk
possibl question manag
signific growth driver drug-coat balloon dcb franchis
context sustain bard legaci busi rate
take recent clinic data releas below-the-kne btk
patient level confid market size bard
previous million opportun
view pend competit boston scientif ranger
abbott/surmod surveil drug-coat balloon market
view drug-elut stent peripher indic could
signific headwind bare stent and/or drug-coat balloon busi
graft chronic dialysi product endovascular fistula creation devic
one bard key product lutonix drug-coat balloon lutonix drug
coat balloon pta cathet current indic percutan translumin angioplasti
de novo restenot in-stent restenot lesion mm length nativ
superfici femor poplit arteri refer vessel diamet mm
novemb becton announc clinic trial data studi lutonix below-the-kne btk
indic europ canada australia lutonix commerci avail
use btk arteri associ critic limb ischemia cii sinc bard submit
pma fda approv expect bard estim market
opportun associ btk indic around million total
opportun dcb excess billion
estim global dcb market million becton disclos
amount dcb sale estim sale million rang
market dcb leader estim sale similar becton
player us market philip acquisit spectranet acquir
dcb program covidien part mandat divestitur associ
deal believ philip neglig market share outsid unit state boston
scientif ranger dcb approv ce mark sinc juli
state aim approv unit state also
drug-coat balloon surveil develop partnership
surveil dcb like receiv european approv around year end fda
approv
system fda-approv superfici femor arteri sfa full poplit arteri
bard e-luminexx vascular stent indic treatment iliac occlus diseas
patient common and/or extern iliac arteri
compani pursu develop drug-elut peripher stent
cook medic privat cover receiv fda approv zilver drug-elut stent
novemb boston scientif receiv fda approv eluvia drug-elut stent
septemb fda approv base imperi trial result show
eluvia superior zilver term rate primari patenc rate
versu respect well significantli lower rate target lesion
possibl question manag
challeng around dose captur insulin pen technolog
lead repriorit product still viabl opportun longer
investor think near long-term market opportun
swatch
talk featur benefit swatch patch pump product
rel drug patch technolog market like valerita v-go
former j/calibra medic cequr onetouch via make
better product and/or one capabl greater adopt
look integr continu glucos monitor technolog onto
becton diabet busi repres approxim total compani sale includ
syring pen needl use inject insulin drug use treatment
diabet
throughout histori diabet area focu becton dickinson
compani explor way expand busi
earli interest blood glucos monitor market
januari compani announc two new fda-clear blood glucos monitor
product bd logic blood glucos monitor bd latitud diabet manag
bd also announc enter two separ unrel strateg
relationship increas diabet care market presenc
respect term agreement distribut co-brand
version bd logic blood glucos monitor bd strip compani collabor
develop integr system respect lilli term lilli use
 diabet sale organ provid target support market introduct
new bd latitud diabet manag system lilli bd would jointli pursu
futur opportun diabet diseas manag becton endeavor blood glucos
monitor continu decid septemb halv effort bd
manag conclud futur outlook increasingli competit market
justifi level invest addit resourc necessari continu
right call view bgm market would subsequ come intens price
pressur owe medicar reimburs chang
becton also sought expand diabet infus set use
conjunct insulin pump deliv insulin becton collabor jdrf
develop bd flowsmart technolog featur side-port cathet design
improv insulin flow reduc number flow interrupt bd flowsmart technolog
approv canada januari april part agreement
bd commerci set infus set recal due
issu compon becton work redesign set howev becton announc
novemb would discontinu product redesign provid
level differenti set hope
becton also made effort partnership jdrf relat continu blood
glucos monitor well combin devic continu blood glucos monitor
infus devic bd perform trial use glucose-bind protein-continu
becton also work dose captur insulin pen product smart pen becton
product smartsens needl would flow-sens technolog would
abl captur amount insulin dose deliv product design
univers fit dispos insulin pen howev compani februari
announc made decis stop program reassess near-term commerci
opportun rather decid deploy resourc smart type patch pump see
comment would return back pen program later date
becton also focus insulin deliveri system design type ii patient
patch pump swatch design adjust basil bolu rate patch
design wear becton state design product low cost
near price pariti current therapi pen novemb becton comment
track submit regulatori approv us eu come month
becton current plan swatch us launch around end calendar
compani launch attempt launch insulin
patch technolog gear type ii patient popul
valerita cover current sell v-go wearabl insulin deliveri devic v-go
once-daili patch offer basal rate steadi rate insulin hour also
abil provid addit insulin mealtim click button v-go
classifi durabl medic equip reimburs
medicar part v-go first commerci unit state view
compani sale trajectori less market hope valerita
revenu total million gross margin
cequr privat cover swiss compani also work
commerci insulin deliveri devic paq patch devic deliv basal
bolu inject insulin day paq devic receiv ce mark
 cover goeff meacham develop insulin deliveri patch target
type patient acquir patch-mak calibra medic target
launch product brand name onetouch via howev decid exit
diabet devic market place sold calibra asset cequr juli cequr
expect launch system new name mid devic three-
day insulin deliveri patch provid bolu insulin deliveri devic deliv on-
demand mealtim bolu unit increment hold unit fast-act
possibl question manag
manag see sustain rate busi go forward
past year better-than-market taken share
infus pump medic manag pyxi current rate
growth sustain busi revert lower at-market rate
would character competit dynam infus pump
competit disadvantag broad offer infus solut
would compani consid get infus solut market
meaning way agreement freseniu
dispens technolog infus system estim sale roughli split
two busi
dispens technolog busi includ primarili system sold bd
pyxi brand major sale unit state bd pyxi
medstat autom medic dispens system typic maintain
access nurs unit bd also sell system medic suppli manag
call pyxi supplyst pyxi signific market share posit like greater
medic manag unit state main competitor
cover outsid unit state bd also offer rowa robot
medic storag retriev system retail hospit pharmaci
infus system includ infus pump sold hospit ambulatori
surgeri center transport servic becton largest instal base larg
volum pump unit state alari system primarili sold
unit state smart pump system allow simultan iv medic
fluid administr multipl deliveri modul syring pump larg volum
pump patient control analgesia pump pump use dedic dispos
administr set thu becton benefit sale pump up-front
enjoy long-term revenu stream dispos outsid unit state
becton market caesarea medic electron pump infus syring
expand bd busi ambulatori home specialti acut care infus
pump unit state primari competitor infus pump
baxter baxter recent launch new infus pump spectrum
possibl question manag
would manag will spin divest diagnost system
key new system new assay launch expect
preanalyt system includ blood collect product system
product sold hospit laboratori clinic
diagnost system includ autom blood cultur tuberculosi cultur
assay liquid-bas cytolog system cervic cancer screen blood
cultur busi largest part diagnost includ compani flagship bd
bactec system bd molecular platform includ bd bd viper lt system
bioscienc includ fluorescence-activ cell sorter analyz reagent
molecular index next-gener sequenc sampl prepar genom
diagnostic/monitor reagent analyz product typic sold
pharmaceut biotechnolog compani well academ govern
institut research clinic tool use studi cell cell compon
aid discoveri develop new drug and/or improv diagnosi
manag diseas
co
margin return data
balanc sheet cash flow mn
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
equal weight believ bd
success integr bard achiev plan
synergi though market alreadi appreci
base success integr carefus
ep recalibr think
street forecast may still high
see upsid near-term enough
warrant chang view rate ew
upsid case could driven better-than-
bard acquisit improv overal
growth rate higher earn
downsid case could driven foreign
exchang stronger us dollar could pressur
expect sale legaci bard busi
slowdown emerg market growth
inabl off-set gore royalti
price pe perform
conm corp quarterli annual ep usd
consensu number refinitiv receiv gmt
share struggl compani went proxi battl novemb curt hartman name presid
ceo initi enthusiasm around prospect turn around drove share higher though perform
consist lead stock trade lower sideway throughout made progress
turnaround sale growth acceler lead stock move higher
sale product categori
sale geographi
market size main competitor
devic repair soft tissu injuri joint particularli
knee shoulder
exclus commerci right mtf allograft tissu use
surgic drill saw relat singl use cut
high-definit surgic visual system enabl
platform devic accessori creat enter
surgic work space minim invas procedur
mainli also depuy synth
rf energi affect tissu cut seal caus
hemostasi open minim invas procedur
instrument accessori minim invas
laparoscop open robot approach
therapeut diagnost endoscop product use
single-us devic monitor cardiac activ
sale street deliv solid quarter report
growth constant currenc growth ep in-lin
street expect organ constant currenc growth
full year ep rang guidanc includ impact buffalo
addit detail quarter
million except per share data chang sale constant currenc organ basi unless otherwis note
constant currenc growth reflect gener surgeri sale growth
orthoped surgeri growth
manag expect constant currenc sale growth ep guidanc
street consensu
manag express confid new product encourag attend
aao march
despit top-lin beat ep line expect manag reinvest
upsid back busi
gross margin bp due manag still anticip
margin expans
sale y/i constant currenc basi extra
sell day contribut sale growth
gross margin y/i time manufactur varianc
caus occasion lumpi gross margin
sg sale y/i despit invest custom
 sale y/i compani plan increas invest
oper margin y/i
ebitda margin y/i
adjust tax rate y/i guidanc
adjust ep in-lin street consensu
manag note one less sell day
conm guidanc reflect impact buffalo filter acquisit manag expect constant currenc revenu growth
headwind fx ep guidanc street releas manag
expect gross margin expans sg decreas oper margin expans
interest expens ex buffalo tax rate year
turn around well-posit
deliv sale growth least mid-singl digit double-
sale growth comparison becom challeng ahead
could find difficult grow
acquisit buffalo filter add potenti long-term driver
compet much larger compani
growth leader grow smoke evacu
market legisl guidelin updat could drive increas
adopt smoke evacu product
smaller compani given financi outlook
could find possibl target med-tech
market consolid
compani may success integr effort
buffalo filter and/or smoke evacu opportun
may less expect
success execut turnaround posit deliv least mid-single-digit
sale double-digit ep growth view acquisit buffalo filter posit
enhanc underli growth rate also confid manag abil
integr buffalo filter given success integr surgiquest acquisit outperform
investor expect extent sustain least mid-singl digit growth
compani could acquisit candid med-tech remain consolid market
american academi orthoped surgeon aao
apr societi american gastrointestin endoscop surgeon sage meet
possibl question topic manag
put take investor consid manag
current think financi impact buffalo filter acquisit
investor think long-term growth profil compani
manag target long-term term margin profil busi
structur challeng obtain higher oper margin profil
given focu product pipelin new launch particular product
segment see particular enhanc strength given recent upcom launch
see challeng integr buffalo filter acquisit
potenti synergi posit surpris transact
prior purchas focus pay debt current focu use
capit view futur capit deploy opportun
particular segment focus enhanc growth would
look extern obtain favor growth profil
possibl questions/top manag
possibl question manag
put take investor consid
manag current think financi impact buffalo filter
investor think long-term growth profil compani
consid recent acquisit buffalo filter
manag target long-term term margin profil
busi structur challeng obtain higher oper
conm tax rate fairli high rel med-tech compani
opportun reduc time horizon
januari manag provid initi guidanc includ
then-pend acquisit buffalo filter manag expect deliv
constant currenc growth see headwind fx rate manag
expect gross margin expand see opportun reduc sg
spend percent sale net/net manag expect oper
margin expans ep perspect manag expect earn
februari complet acquisit buffalo filter buffalo filter
gener million sale exclud million sale million
ebitda time acquisit manag expect buffalo filter sale
entir period million expect ebitda million
manag expect deal accret oper margin
given increment debt fund deal manag expect deal neutral
adjust ep given higher top line growth margin profil see
increment margin expans manag expect deal
accret ep think baselin estim
could upsid success integr
possibl question manag
manag strateg vision compani
manag view compani current busi mix
quickli expect de-lev compani follow buffalo filter
deal import futur compani
past four year execut turnaround plan led curt
hartman appoint presid ceo hartman first prioriti
invest human capit end appoint sever new season execut
strategi also includ make customer-centr innovative-driven
hartman restructur market leadership align market product strategi road
map re-invigor product pipelin enhanc sale manag hire in-countri
leadership critic export market focus oper model hartman strategi
also includ restor busi develop function complet number
transact product line addit januari conm
acquir surgiquest airseal system airseal system consist valve-fre trocar
continu pressur sens integr insuffl smoke evacu use
laparoscop robot procedur success integr surgiquest
airseal contributor compani improv growth recent
februari complet acquisit buffalo filter lead manufactur
surgic smoke evacu system like surgiquest believ buffalo filter enhanc
growth outlook year come also expect continu contribut
new product result revamp effort
possibl question manag
manag believ larg enough resourc well enough
compet larger medic devic compani end market
illustr figur compet end market includ larger medic
devic compani includ zimmer biomet smith nephew
possibl question manag
manag view competit landscap smoke evacu
manag view long-term opportun buffalo filter
potenti legisl and/or guidelin changes/recommend
could drive adopt smoke evacu product
integr strategi manag ensur smooth
integr process learn surgiquest appli
integr
februari acquir buffalo filter million buffalo filter lead
manufactur surgic smoke evacu technolog approxim share
million stand-alone smoke evacu market
surgic smoke gener surgic procedur use energy-bas
devic cauter vessel vapor human tissu bodili fluid caus surgic
smoke smoke contain toxic chemic benzen toluen carbon monoxid etc
along aerosol pathogen small particl absorb patient
bodi laparoscop endoscop procedur see protect patient
surgic smoke signific hazard patient surgic staff unit state
healthcar worker expos surgic smoke everi year accord
occup safeti health administr osha studi perform quantifi
health risk smoke oper room show cauter gram tissu
produc smoke equival unfilt cigarett journal articl studi
smoke exposur uk plastic surgeri unit reveal daili smoke produc present
despit hazard surgic smoke use surgic smoke evacu equip
univers standard fact use smoke evacu estim approxim
penetr us intern research studi factor
imped adopt smoke evacu technolog studi publish aorn
kay barrier adopt includ physician equip believ avail equip
noisi staff complac inconveni
around world govern regulatori bodi profession organ
write law guidanc relat surgic smoke denmark surgic smoke remov
mandat law canada smoke remov becom requir standard care
australia new zealand uk establish regul legal enforc
protect hospit employe smoke unit state nationwid regul
current exist although state start adopt legisl exampl rhode
island pass law requir or smoke free california pend regul
conjunct osha regulatori bodi establish surgic smoke
safeti issu cover guidelin surgic smoke legisl also propos
colorado massachusett addit nation institut occup safeti
niosh part cdc establish practic surgic plume
remov joint commiss accredit certifi healthcar organ
written standard smoke laser/electrosurg procedur associ
periop regist nurs establish guidelin surgic smoke safeti
anticip continu momentum surgic smoke restrict guidelin
global tailwind surgic smoke remov devic sale
possibl question manag
key new product improv compani
product focu upcom american academi
orthoped surgeon aaso confer and/or upcom industri
greatest opportun spend area like
alloc dollar area might requir extern acquisit
past sever year manag refocus effort new
product contribut acceler overal sale growth
recent new product within orthoped surgeri busi
includ
crystalview fluid manag system orthopaed procedur visual
trushot soft tissu fixat anchor deploy y-knot self-punch sutur
anchor within orthoped segment gener surgeri continu
roll-out surgiquest system earn call manag mention strong
first half orthoped product pipelin express excit
announc plan provid detail product pipelin aao
margin return data
balanc sheet cash flow mn
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
overweight success
execut turnaround posit deliv
mid-single-digit sale double-digit ep growth
view acquisit buffalo filter posit
enhanc underli growth rate
upsid case could driven continu
success drive mid singl digit sale growth
continu strengthen us orthoped
improv new product contribut
greater expect
downsid case could driven slowdown
organ growth comp becom difficult
slowdown hospit capit equip market
invest spend drive futur growth
foreign exchang rate strengthen us dollar
higher tax
edward lifesci corp ew quarterli annual ep usd
consensu number refinitiv receiv gmt
price pe perform
perform ew shre historiclli turn mileston relat transcathet heart valv program earli
approv sapien xt success patent litig trial result show superior corevalv
versu surgeri approv better expect tavr sale result drove stock higher share sold octob
compani releas result street expect stock recov tavr util trend continu increas recent
share appreci anticip posit result compani trial evalu sapien valv patient
determin low risk open heart surgeri outlook compani mitral valv replac repair pipelin
sale product categori
sale geographi
less-invas transcathet aortic valv primarili sapien brand edward also self-expand
transcathet valv centera brand
transcathet valv treatment design use mitral tricuspid valv product includ
cardioband pascal
segment includ surgic mitral aortic valv replac repair technolog
critic care product includ hemodynam monitor system measur heart function fluid
surgeri
trans-cathet aortic mitral tricuspid heart valv barclay medic suppli devic
sale street mainli driven higher critic structur heart
valv sale thvt sale in-lin underli sale ep
line street estim toward upper end
guidanc rang edward re-affirmed full year guidanc rang
provid analyst day decemb guidanc street
expect net/net noth chang view outlook
million except per share data chang sale constant currenc organ basi unless otherwis note
addit detail quarter
previou guidanc rang re-affirmed
gross margin improv y/i benefit foreign exchang
hedg product mix absenc expens closur swiss
manufactur plant off-set invest capac
critic sale better-than-expect underli sale growth
led hemospher growth enhanc recoveri product
transcathet heart valv therapi thvt sale in-lin street
dollar basi constant currenc basi growth littl lighter
manag target thought growth would line
trend think market hope mayb given
continu roll-out albeit control centera sapien ultra
manag guid metric street see detail
ew note lost share europ y/i basi maintain price
disciplin note share sequenti stabl
sale underli basi underli growth divis
transcathet heart valv therapi structur heart critic
gross margin y/i benefit fx rate
sg sale y/i
 sale y/i edward continu invest clinic trial
transcathet structur heart program
oper margin y/i larg driven oper expans
effect busi manag
adjust tax rate y/i includ benefit
adjust ep in- line street estim
edward expect sale versu street pre-releas ep versu street pre-
edward reiter full year guidanc rang continu expect sale rang underli
though currenc expect slightli less headwind versu underli basi ew expect transcathet
aortic valv replac tavr growth surgic structur heart growth critic growth
transcathet mitral tricuspid therapi tmtt sale expect gross profit margin anticip
oper margin adjust tax rate expect net/net ew maintain adjust ep target
trancathet aortic valv
replac tavr market best technolog
tavr market expect doubl next sever year
technolog move lower risk patient greater
adopt overal treatment
edward number shot goal mitral tricuspid
repair replac system transcathet mitral
tricuspid market could larger tavr
edward could acquisit target given potenti long-
market alreadi expect favor result non-inferior
superior low risk trial
market underestim impact new entrant
tavr market compani compet space
transcathet mitral valv market may take longer develop
numer compani develop tmtt devic
believ sale growth like slow edward face competit transcathet aortic valv
tavr expect limit leverag edward invest transcathet mitral valv tmvr/r
opportun sale ep estim street tmvr/r repres potenti second
act still risk like crowd space
american colleg cardiolog meet releas risk trial
result edward host investor meet march
april dgk meet german cardiolog day pascal data expect present
may europcr meet month pascal data expect present
launch lotu eu receiv pma approv us
on-going updat abt/pasc patent litig
possibl question topic manag
think guidanc manag feel greatest level confid
achiev greatest amount uncertainti
investor think long-term growth profil compani
forecast tavr market doubl much growth come increas
awar new patient versu convert patient surgic penetr rate
forecast tavr versu surgeri
expect market share year assum abbott lab
avail unit state expect intern
expect sale ramp-up transcathet mitral repair replac well
tricuspid repair primarili mitral repair sale forecast expect mitral market
split term repair versu replac
earli ce mark pascal system impact tmtt sale goal
million abbott litig impact launch strategi pascal
relev date relat law suit go forward
see potenti timelin us market cardioband pascal sapien
evoqu
possibl questions/top manag
possibl question manag
think guidanc manag feel greatest
level confid achiev greatest amount
extent upsid forecast manag like reinvest
back busi could fall bottom line
investor think long-term growth profil compani
earn call edward reiter guidanc initi provid
compani decemb investor day edward expect sale
billion underli basi ep figur illustr
sg sale
 sale
compani expect sale rang million ep
rang
edward manag also provid long-term guidanc commentari analyst day
expect grow sale consider higher organ basi industri averag
expect mix effici lift gross margin longer term percent
sale declin expect futur sale growth exceed growth edward
continu expect invest clinic trial expand indic develop new
technolog sg spend percent sale expect stay roughli consist
project level long term edward leverag sale remain
disciplin control sg growth off-set addit invest support
innov net/net edward expect oper margin expand modestli time
tax rate expect increas though manag note less predict due
stock option account potenti polici chang
possibl question manag
forecast tavr market doubl much growth come
increas awar new patient versu convert patient
surgic penetr rate forecast tavr versu surgeri
thought outcom low-risk trial result
sale centera track europ abl obtain premium
price across variou market
centera allow gain share self-expand valv
cannib market share
strategi roll sapien ultra europ well unit
forecast market share loss go forward boston
scientif launch lotu edg global acur tavr valv
us forecast abbott portico valv
edward tavr busi repres approxim total sale engin
growth almost decad
tavr market total approxim billion edward expect tavr
market continu grow doubl size billion impli compound-annual-growth-rate
driven indic expans increas awar improv technolog
put take edward tavr busi
look ahead edward tavr busi like tailwind also
indic expans edward two trial underway could pave way
indic expans first trial low-risk trial evalu
safeti effect sapien valv versu tradit surgic aortic valv
replac savr patient symptomat sever calcifi aortic stenosi
low oper risk data trial expect present
american colleg cardiolog annual meet march manag
expect posit data expect fda grant low-risk indic late
also expect releas interim result low-risk studi
confer well second trial earli tavr trial enrol
patient sever aortic stenosi asymptomat studi
enrol earli decemb expect complet enrol
patient random tf-tavr arm clinic surveil primari
endpoint superior composit all-caus death stroke unplan
edward new tavr introduct edward receiv ce mark european approv
centera self-expand valv februari roll product
control manner edward price valv premium sapien
competit product edward also receiv ce mark sapien ultra valv
novemb though note also launch product control roll-out
sapien ultra edward next-gener balloon-expand valv includ
improv skirt design intend improv paravalvular leak promot tissu in-
growth system also on-balloon deliveri system expand sheath
edward receiv fda approv sapien ultra end decemb
increas competit look ahead edward like face increas tavr
competit boston scientif
expect limit re-launch lotu edg europ march
pend fda approv expect control launch earli
expect receiv ce mark acur includ advanc pvl
seal technolog boston scientif enrol repris iv
intermediate-risk studi expect complet enrol second
one acur studi intermediate- high- extreme-risk tavr
patient use support acur us approv
expect begin
abbott expect data portico us trial present tct meet
fall portico trial includ high risk extrem risk
patient random either portico valv commerci avail valv
edward sapien corevalve/evolut abbott also evalu next-
gener flexnav deliveri system addit patient abbott plan
launch portico unit state earli
also continu develop next gener tavr devic
expect launch next gener evolut pro fiscal
possibl question manag
thought need cerebr protect system tavr
view
lack cerebr protect system competit
past concern regard incid stroke associ tavr
procedur sever compani develop cerebr embol protect system
design filter captur remov and/or deflect embol debri tavr procedur
edward acquir embrella cardiovascular march million embrella
cardiovascular develop embrella embol deflector
design deflect embol materi transcathet valv procedur embrella
system receiv ce mark may edward commerci devic
unit state edward posit cerebr protect system compani
sure whether materi improv sapien perform given stroke rate
acquir claret medic august million up-front cash
million reimbursement-bas mileston payment claret medic sentinel
cerebr protect receiv ce mark fda clearanc
sentinel filter captur remov embol debri releas tavr center
medicar medicaid servic grant new technolog add-on payment
design sentinel took effect octob institut argu
wide spread use devic
possibl question manag
assumpt billion tmtt market expect
sale ramp mitral repair replac well tricuspid repair
play primarili mitral repair sale forecast expect
mitral market split term repair versu replac
tmtt program feel optimist today
earli ce mark pascal system impact tmtt sale
goal million
abbott litig impact launch strategi pascal
relev date relat law suit go forward
latest updat cardioband suppli issu product
full transfer exist edward manufactur locat
see potenti timelin us market cardioband
pascal sapien evoqu long expect clinic trial
enrol take might studi endpoint
demograph suggest transcathet mitral tricuspid therapi tmtt market could
larger tavr market edward estim million patient
us alon moder sever mitral regurgit mr tricuspid regurgit
tr moreov estim today patient signific mr tr
treat us edward estim tmtt global market opportun could
billion size reach billion frame refer estim
abbott transcathet mitral valv repair mitraclip sale roughli million
surpass million edward target million tmtt sale
edward activ research transcathet mitral valv therapi date back
least earli edward acquir percutan mitral valv repair program
jome februari even acquisit pvt complement exist
program edward also acquir asset percutan mitral valv program
sinc edward acquir cardiaq valv technolog valtech cardio
harpoon medic acquisit valtech one
approv deviceth cardioband system receiv ce mark european
approv septemb
edward current four transcathet mitral valv program develop three
transcathet tricuspid program develop summar figur
edward transcathet mitral tricuspid valv program
transcathet devic focus reduc mitral
regurgit annular reduct
mitral valv leaflet repair system includ
spacer paddl clasp
sapien mitral replac mitral valv replac system leverag
edward sapien aortic valv platform
incorpor dock station design
built learn experi forti
intern program cardiaq acquir
 activ pivot trial current paus evalu
 ce mark approv februari roll-out
 clasp ce mark data expect march may
 us pivot clasp iif fmr initi expect late
 earli feasibl studi us
 initi pivot trial late
 continu earli feasibl studi
design implant techniqu use
cardioband mitral system
 ce mark april
 activ tr pivot trial initi late
 tricuspid earli feasibl studi enrol
repair system consist foam-fil
polym balloon spacer rail anchor
right ventricular apex
 return earli feasibl studi follow system
cardioband annual reduct system receiv ce mark mitral repair
tricuspid repair edward believ cardioband sale could reach
million howev manufactur suppli constraint decis shift product
anoth edward facil result sale million edward anticip
total mitral tricuspid sale million howev meaning portion come
launch pascal europ
decemb edward announc paus enrol cardioband
activ mr us pivot trial evalu trial design light abbott mitraclip result
activ trial origin design includ patient clinic signific
function mitral regurgit patient would random receiv either
cardioband system plu guidelin direct medic therapi gdmt gdmt alon
primari outcom measur preval mr hierarch comparison
devic control group includ time cardiovascular death number heart failur
hospit improv mwt distanc meter kccq number point
improv one year
edward expect initi us pivot trial cardioband use treat tricuspid
regurgit activ tr late
pascal system transcathet mitral valv leaflet repair system includ spacer
paddl clasp mitral valv leaflet februari
pascal system receiv ce mark treatment patient mitral regurgit
approv came earlier expect await data pascal ce mark
studi data expect dgk german cardiolog confer april
data expect europcr confer may data
european compassion use case demonstr stabl improv nyha
class mr grade month
compani earn call edward announc begun treat patient
clasp iid us pivot trial studi enrol least patient symptomat
primari degen mitral regurgit deem candid mitral
valv surgeri patient select criterion consist current label indic
mitraclip pre-coapt trial random edward pascal abbott
mitraclip edward also evalu patient suitabl pascal separ
arm studi
edward also plan pursu clasp iif fmr pivot trial would evalu
patient secondari function mitral regurgit edward expect initi trial
late anticip trial would also random mitraclip may gain
label indic function mr base coapt studi result
januari abbott file patent litig suit edward claim
pascal system infring multipl abbott patent cover mitraclip system
unit state lawsuit claim pascal infring five abbott patent patent number
patent patent patent
patent patent abbott seek monetari
damag well preliminari perman injunct abbott also file suit
edward unit kingdom germani switzerland
edward two program develop area transcathet mitral valv
replacementth sapien platform base sapien tavr platform evoqu
base legaci intern forti platform acquir cardiaq platform
platform design use via transfemoral/transept approach earli
feasibl studi valv platform underway edward expect initi us
pivot trial sapien late
possibl question manag
investor think manag alloc capit near
intermedi term
investor expect continu share repurchas activ primari use
free cash flow
structur heart failur outsid heart valv area interest edward
regard capit alloc edward first prioriti invest intern innov
program second supplement intern invest minor
invest novel technolog excess cash use repurchas share
harpoon medic decemb aggreg purchas price million
includ million paid previous net million receiv
sale previou ownership interest edward may pay addit
million pre-specifi mileston payment next year
valtech cardio ltd januari million potenti addit
million pre-specifi mileston payment decemb edward record
million impair charg relat valtech asset prior close
transact valtech spun early-stag transsept mitral valv replac
technolog edward enter agreement exclus option acquir
program associ ip approxim million plu addit million
certain eu regulatori approv obtain within year acquisit close date
option origin set expir two year close transact
extend one year edward expect net cash inflow begin
cardiaq valv technolog august cash purchas price million
addit million certain eu approv obtain within month
acquisit close date howev edward expect mileston
achiev edward expect net cash inflow would begin late howev due
certain design enhanc edward incur addit expens
expect increas net cash inflow relat project begin
decemb edward million cash cash equival well
short term invest edward anoth million long-term invest total
debt total million edward repurchas nearli million share
margin return data
balanc sheet cash flow mn
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
underweight believ sale growth like
slow edward face competit transcathet
aortic valv tavr expect limit leverag
edward invest transcathet mitral valv
tmvr/r opportun sale ep estim
street tmvr/r repres potenti
second act still risk like
upsid case may driven better-than-
expect tavr sale greater leverag
stronger uptak tmvr europ faster-
than-expect time tmvr/r product
downsid case may driven delay
inabl commerci tmvr/r technolog
slowdown tavr sale due market slowdown
and/or competit pressur fx rate
greater expens support tmvr/r
price pe perform
hill-rom hold inc quarterli annual ep usd
consensu number refinitiv receiv gmt
share appreci past five year compani evolv busi mix aquisitoin sever compani
notabl welch allyn recent increas stock attribut view instal john groetelaar ceo
may mr groetelaar previous bard
sale product categori
sale geographi
surfac softwar solut
segment includ patient monitor diagnost product respiratori health product design
treatment environ rang primari care home care
product segment includ oper room capit equip like surgic tabl light oper
room posit devic along dispos product like scalpel blade skin marker integr tabl
motion surgic tabl pair da vinci xi robot key product segment
patient support line barclay medic suppli devic
sale street sale grow report basi
constant currenc basi core basi ahead compani guidanc
report growth constant currenc growth core growth ep
compar basi adopt ep
street estim estim compani guidanc
rang re-affirmed revenu growth guidanc
lower ep guidanc sole due adopt
addit detail quarter
million except per share data chang sale constant currenc organ basi unless otherwis note
growth hill-rom defin guidanc reflect
growth patient support system front surgic
consecut quarter double-digit growth across key capit product us
includ med-surg bed system clinic workflow solut safe patient
hill-rom sale new product track target
new product exceed object year earli
ep guidanc rang street releas estim
estim manag note half
expect impact full year relat adopt would occur
despit beat manag lower ep reflect
adopt manag note intent meet beat guidanc
quick recap adopt basi current year ago
total sale report basi constant currenc core
growth basi growth across busi patient support system
front surgic solut
gross margin y/i due posit contribut mix
manufactur product procur effort
sg sale y/i strateg invest off-set
 sale even y/i basi
oper margin y/i
adjust tax rate y/i tax rate lower expect
reflect benefit stock base compens
adjust ep basi adjust ep
street estim estim
hill-rom expect report sale growth flat constant currenc sale growth core revenu growth ep
expect guidanc releas street revenu ep
hill-rom continu expect report sale growth constant currenc sale growth core revenu growth
hill-rom updat ep guidanc sole reflect impact adopt ep expect
john groetelaar current ceo come hill-rom
histori success bard help compani expand
intern sale base leadership posit
despit increas new product hill-rom core growth
rate last three year
hill-rom portfolio may translat well bard
hill-rom increas contribut new product
effort expand geograph
recent year continu contribut acceler
opportun margin expans roughli
million potenti addit cost flexibl reinvest
valuat reason extent compani
acceler top line there room multipl expans
addit invest may need acceler top line
growth rate compani invest could either
form higher spend sale market
spend extern sourc
view compani may continu struggl increas core sale growth
may necessari rate stock equal weight
possibl question topic manag
mr groetalaar view compani sinc join organ
posit neg find sinc join mr groetelaar believ add
ms bodem initi impress hill-rom financ organ strength
ms bodem bring hill-rom
manag see greatest opportun drive upsid intern
expans increas sale market spend increas
view current spend hill-rom need increas alloc
order acceler core busi
manag believ increas activ need help acceler sale
growth profil compani type interest
possibl questions/top manag
possibl question manag
mr groetalaar view compani sinc join organ
posit neg find sinc join
strateg vision hill-rom
ms bodem
impress hill-rom financ
organ strength ms bodem bring hill-rom
john groetelaar appoint presid ceo hill-rom effect may
recent serv execut vice presid presid becton dickinson
intervent segment join decemb follow acquisit
bard inc mr groetelaar spent previou year number role bard
includ group presid among respons improv
bard emerg market exposur emerg market increas
total sale acquisit becton dickinson prior bard mr groetelaar
work guidant
barbara bodem appoint senior vice presid cfo hill-rom effect
decemb ms bodem join hill-rom serv
senior vice presid financ past three year prior ms bodem
work hospira vice presid global commerci financ well
held varieti financ role includ serv cfo lilli
possibl question manag
manag see greatest opportun drive upsid
intern expans increas sale market increas
manag strategi expand intern region
product line hold greatest potenti intern
view current spend hill-rom need increas
alloc order acceler core busi
manag believ increas activ need help
acceler sale growth profil compani
regard focus tuck-in larger deal new
adjac area less attract
hill-rom revenu current heavili skew market
revenu emerg market mr groetelaar note see under-penetr
latin america asia pacif specif two region repres
headwind fiscal larg due inventori manag issu compani
make improv inventori manag system region
complet complet fiscal hill-rom key product
regist latin america asia pacif region limit impact
 expens percent revenu declin
annual current guidanc fiscal increas
larger percentag spend shift toward project front spend
relat centrella launch declin long-term manag view margin
appropri
decemb hill-rom million cash equival million
total debt net leverag past sever year primari use free cash
flow de-lever septemb acquisit welch allyn left hill-rom net
leverag take opportunist approach acquisit
compani note pipelin mostli tuck-in bolt-on opportun
also acquisit capac compet larger transact estim acquisit
capac approxim million
possibl question manag
confid guidanc area feel
least confid deliv
investor think long-term growth profil compani
anyth chang long-rang plan tax rate
drive core growth higher rang given compani
histori grow core
novemb hill-rom provid long-rang plan lrp includ sale growth
margin ep aspir manag subsequ updat lrp
revenu exclud foreign currenc divestitur exit non-strateg asset third-parti rental third-
manag expect core revenu defin revenu exclud fx acquisit
divestitur exit non-strateg asset acceler compound-annual-growth-rate
fiscal revenu constant currenc basi hill-
rom estim core revenu hill-rom expect revenu growth acceler
driven steadi cadenc new product partnership
fiscal hill-rom expect constant currenc growth core revenu
growth definit core revenu exclud specialti intern
oem busi benefit core growth rel past definit hill-rom
expect oper margin expand improv occur
gross margin hill-rom expect adjust tax rate includ
benefit stock base compens hill-rom expect adjust ep rang
increas year-over-year basi adjust
benefit relat stock base compens fiscal ep growth fiscal
closer
hill-rom forecast report revenu growth flat versu constant
currenc growth approxim core growth approxim adjust ep
expect rang adjust benefit stock-
base compens guidanc impli adjust ep growth
possibl question manag
key new product drove new product sale million
fiscal ahead compani million guidanc much
pipelin addit vs cannibalist
look ahead new product hold greatest growth potenti
hill-rom gener million new product fiscal hill-rom initi guidanc
new product contribut fiscal million howev compani
exceed level achiev million fiscal hill-rom guidanc includ
million new product contribut lrp fiscal estim million
compani gener million new product track guidanc
hill-rom defin new product launch sinc product alreadi
launch includ connex monitor vision screener retinavu vesivest
trusystem surgic tabl linq mobil product expect
approv next two year includ next-gener surfac watchcar
assess revit vital sign patch next-gener respiratori therapi
centrella smart medsurg bed system within pss key driver sale
centrella bed launch centrella launch fall manag believ
acceler replac cycl us bed design new
technolog enabl nurses/physician better prevent patient fall
enhanc surfac help reduc pressur ulcer skin deterior
issu centrella gener million revenu sinc launch
centrella sale account approxim us medsurg revenu
would expect continu strength us fiscal also believ could
growth intern hill-rom expand sale focu middl east
retinavu retinavu network welch allyn acquir hubbl telemed januari
hubbl telemed call retinavu network combin
softwar specialist network allow point-of-car retin scan detect
diabet retinopathi encrypt scan sent state-licens board-certifi
ophthalmologist turn send physician diagnost report fundu imag
code recommend referr care plan scan complet
process typic complet minut retinavu imag launch
march hand held fundu camera low power microscop camera use
photograph retina cost approxim less tradit
desktop fundu camera manag size us diabet popul approxim
million believ retinavu could becom million-plu per year product
hill-rom announc new partnership siemen healthin market leader
test us retinavu imag includ suit diabet
instrument provid proactiv test treatment singl visit product
gener revenu sale devic well fee per screen fiscal
hill-rom invest person dedic sale team retinavu note
devic placement increas doubl digit year compani launch
next-gener devic fiscal improv eas use
vision screener vision screener handheld devic design
quickli detect vision issu patient young six month old hill-rom
focus market effort improv earli detect amblyopia
vision disabl children
integr tabl motion hill-rom receiv clearanc
offer integr tabl motion itm da vinci xi surgic system us
januari trusystem design connect da vinci xi
surgic system order allow dynam patient posit surgeri
part agreement intuit offer itm softwar
part da vinci xi sale process softwar sale success hill-rom sale
rep respons close final sale itm tabl current
approxim da vinci xi robot sold itm softwar
high convers rate manag note still larg uninstal base
present opportun itm gener approxim million ad
overal growth itm sale grew manag
expect increas domest da vinci xi penetr well europ
japan
equal weight view compani may
continu struggl increas core sale growth
 may necessari rate
stock equal weight
rate driven new product introduct better-
than-expect margin improv
downsid case driver includ challeng
hospit capital-expenditure environ inabl drive
acceler top-lin growth increas
competit pressur dilut
margin return data
balanc sheet cash flow mn
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
medtron plc quarterli annual ep usd
consensu number refinitiv receiv gmt
price pe perform
last five year share trend higher though price perform chart show far linear reflect
two step forward one step back path announc acquisit covidien june complet januari
past five year fx major headwind compani impact oper margin ep perform progress
made pipelin period overal growth outperform long-rang target although oper margin ep
perform mix
sale product categori
sale geographi
product includ devic design diagnos treat manag heart rhythm disord heart failur
implant cardiac monitor left ventricular assist devic lvad
coronari structur heart product treat coronari arteri diseas heart valv disord includ coronari stent cathet transcathet
aortic valv replac surgic ablat product brand includ corevalv line transcathet
aortic valv resolut drug-elut stent
aortic peripher vascular aortic peripher vascular product treat aortic diseas peripher vascular diseas venou diseas via
graft stent system drug coat balloon carotid arteri embol protect
product includ surgic product stapl devic vessel wound closur electro surgeri
product divis also includ hernia gynecolog product
respiratori monitor airway manag product devic minim invas gastrointestin
procedur treatment renal diseas
spinal implant treat degen disc diseas spinal deform spinal tumor fractur spine
stenosi spine also includ product facilit less invas thoracolumbar surgeri treat condit
cervic region spine biolog solut infus deminer bone matrix product
neurovascular product coil stent devic treat brain aneurysm stroke brain
modul product use treat parkinson epilepsi ocd neurosurgeri product includ
product treat ent diseas control pelvic gastric condit interstim system specialti
surgic product surgeri system aquamanti system
spinal cord stimul implant drug infus system chronic pain intervent product
diabet product design type type ii diabet patient includ insulin pump continu glucos
monitor system diabet manag softwar minim line insulin pump major brand
busi segment
sale street medtron sale report
organ guidanc rang novemb manag
comfort high end rang januari said midpoint
like ep expect driven slightli higher revenu greater
expect favor impact/tim fx/hedg help oper margin
lower tax rate updat forecast see comment
express comfort street ep estim manag remain upbeat
pipelin near term longer term note revenu growth would ramp
given comp product approv time
addit detail quarter
million except per share data chang sale constant currenc organ basi unless otherwis note
oper margin increas y/i adjust basi constant
currenc basi reflect company-wid focu control cost improv
effici result enterpris excel program
continu expect oper margin expans
look off-set headwind product mix mazor dilut china tariff
organ growth solid growth minim invas therapi
restor therapi diabet offset weaker
cardiac vascular group sale
within cvg heart failur declin mid-teen due declin lvad
product due heart transplant guidanc chang share loss
ep guidanc rais though fx expect benefit versu
neutral expect lower tax rate
sale organ basi
gross margin y/i reflect neg mix fx ad
sg sale y/i reflect cost control measur
benefit enterpris excel program
 sale y/i medtron plan continu invest
pipelin view organ highest return invest
oper margin y/i includ benefit
adjust tax rate y/i expect around
/- due benefit final tax owe certain return
adjust ep street midpoint guidanc
ep estimate beat function higher sale
lower tax margin though fx-relat
medtron cvg sale growth similar mitg rtg grow diabet roughli flat due tough
comparison would result overal organ growth around /- fx expect neg impact sale ep
expect
tighten organ sale growth guidanc rang divis expect organ growth
cvg mitg rtg versu previou diabet grow low-to-mid teen ep
guidanc rais fx expect neg impact sale modestli posit
impact margin earn versu prior due benefit hedg program
manag plan releas formal guidanc may along result howev manag express comfort
street ep estim per refinitiv also comment result may back-end load larg due
comp time new product introduct
trade discount med-tech
histori miss-step commun
compani offer attract valuat rel other
around results/expect mix
robust product pipelin allow
compani big constrain overal growth
compani sustain grow long rang plan
rate broader med-tech market
expect rel low
stock reflect conglomer discount
pipelin like acceler growth late
believ number new product across busi allow
sustain mid-single-digit growth expect leverag provid least high-
single-digit ep growth believ stock valuat still attract despit recent
appreci share
american colleg cardiolog meet releas risk tavr
wrap-it trial host investor brief
apr societi american gastrointestin endoscop surgeon sage meet
possibl question topic manag
mandatori retir age ceo posit board
current think success plan
manag look opportun today rel past what
chang anyth invest commun expect tuck-in acquisit
would manag will larger transact
put take fiscal anyth could off-set higher expect
tax rate
investor think long-term growth profil compani
driver deliv organ sale growth oper margin expans
extent upsid organ growth rate would manag inclin let
flow bottom line achiev ep growth excess would manag
look reinvest upsid back busi
key pipelin product critic abil sustain growth
pipelin product could repres upsid success
possibl questions/top manag
leadership success plan
possibl question manag
mandatori retir age ceo
current think around ceo success board
consid optim characterist next-ceo board prefer
intern candid extern candid
medtron board director mandatori retir age
understand execut team may also mandatori retir age
chairman ceo omar ishrak earli
medtron senior leadership team includ age file june
michael coyl age execut vice presid group presid
cardiac vascular group sinc januari inc sinc
decemb prior serv presid cardiac rhythm
manag divis st jude prior posit includ
serv st jude presid compani daig cathet divis numer
leadership posit compani
hooman hakami age execut vice presid group presid
diabet group sinc januari inc sinc june prior
presid ceo detect guidanc solut ge
healthcar april may prior serv presid
ceo intervent system juli april global busi
transform leader ge healthcar decemb juli
vice presid gener manag global ultrasound servic june
decemb mr hakami start career ge held follow
financi role cfo global ultrasound divis cfo
clinic multi-vendor servic well variou financ
role ge capit ge aerospac divis
ge power system
geoffrey martha age execut vice presid presid
restor therapi group sinc june mr martha previous serv
senior vice presid strategi busi develop
begin januari inc begin august prior
serv manag director busi develop ge healthcar
april juli gener manag ge capit technolog financ
servic novemb march senior vice presid busi
develop ge capit vendor financi servic februari
octob gener manag ge capit coloni pacif leas
februari januari vice presid busi develop
potomac feder ge capit feder financ invest bank may
januari
robert ten hoedt age execut vice presid presid emea
compani sinc januari inc sinc may prior
senior vice presid presid emea canada
vice presid cardiovascular europ central asia
vice presid gener manag vitatron gastro-uro leader
market manag neurolog
robert white age execut vice presid presid minim
invas therapi group sinc decemb prior senior vice
presid presid asia pacif januari decemb mr
white held variou leadership posit covidien includ
presid emerg market presid respiratori monitor solut
vice presid gener manag patient monitor mr white also held
variou leadership posit
dr john liddicoat name execut vice presid presid america
region septemb serv member execut
committe dr liddicoat join vice presid atrial
fibril decemb john name vice presid
gener manag structur heart diseas busi soon thereaft
name senior vice presid presid medtron structur heart
divis begin august dr liddicoat serv senior vice presid
presid cardiac rhythm heart failur crhf divis dr liddicoat
cardiothorac surgeon prior join dr liddicoat found two
medic devic compani serv consult sever ventur capit
firm medic devic compani
possibl question manag
put take fiscal anyth could off-set
higher-than-expect tax rate
investor think long-term growth profil compani
driver deliv organ sale growth
extent upsid organ growth rate would manag
inclin let flow bottom line achiev ep growth
excess would manag look reinvest upsid back
confid manag abil drive margin
analyst day june manag provid updat longer-
term expect manag expect drive least organ revenu growth
incorpor view develop market grow emerg market grow low
doubl digit busi group expect cardiac vascular group cvg minim
invas therapi group mitg restor therapi group rtg grow line
corpor averag diabet expect grow faster manag expect
sustain annual underli oper margin expans rang net/net
manag expect adjust ep growth
heart expans target enterpris excel program
announc januari enterpris excel program aim reduc cost
billion fiscal increment annual gross run-rat save expect
million rang fiscal period identifi
three area save
global oper strategi would includ standard best practic
optim qualiti deliveri cost cash flow across manufactur suppli chain
administr facil also includ network optim strateg sourc
save gener vector primarili seen cost good sold
help off-set annual price pressur seen across busi
global function optim includ transform improv product
employe experi area like financ human resourc legal inform
technolog sourc qualiti aim enhanc leverag global
oper model system like share servic save materi cost
good sold sg line
global commerci optim would includ save target evolv go-
to-market model enhanc autom sale process transact
improv product consolid certain common oper
system save vector primarili seen sg line
fiscal current expect organ sale growth rang
adjust ep rang compani expect organ
sale growth would note rel tough comparison
constant currenc revenu growth
plan issu fiscal guidanc along result may
howev manag made sever comment regard fiscal outlook
januari manag note tax regul could put upward bia
effect tax rate manag note fiscal benefit one-tim benefit
underli tax rate around manag comment could
see increas underli rate fiscal could
translat ep growth headwind comment could
mean compani could fall short target ep long-rang growth target
earn call februari manag reiter expect higher tax rate
rang underli rate manag comment
remain confid abil deliv target least organ sale growth
despit pipelin weight second half abil deliv least
underli margin expans line lrp also express comfort
then-consensu ep forecast per refinitiv also note given exchang
rate time expect see sever hundr million advers impact top
line modest impact bottom line
possibl question manag
manag look opportun today rel
past what chang anyth
invest commun expect tuck-in acquisit would
manag will larger transact
manag state target return least free cash flow sharehold
via share repurchas dividend year-to-d paid billion dividend
billion net share repurchas total pay-out ratio respect
acquisit seem manag focus tuck-in acquisit
possibl question manag
see long term growth outlook diabet busi
time achiev factori calibr elimin finger stick
confirm guardian cgm system
follow earlier-than-expect approv june launch medtron minim
hybrid close loop type insulin system expect diabet group
gener double-digit growth throughout fiscal howev suppli constraint relat
associ guardian connect continu glucos monitor cgm sensor well
shipment relat compani prioriti access program limit initi uptak
instead doubl digit growth diabet revenu declin low-single-digit
issu prove transitori diabet segment sale inflect grow
respect j/animass exit pump market
name partner choic also help growth diabet
manag believ roll-out still earli inning expand indic
market penetr drive growth also see increas cgm sensor
util attach rate driver continu sale growth go forward
continu launch minim new ou market
expect releas next gener sugar iq algorithm expect
launch advanc hybrid close loop system design improv time-in-rang
bluetooth enabl minim
also work person close loop pcl system receiv
breakthrough design fda februari expect provid
detail around project american diabet associ ada
june launch first stand-alon gcm guardian connect
sugar iq cgm system measur glucos level everi five minut display
associ mobil app current system still requir finger stick calibr
well finger stick confirm wherea compet cgm system abbott
freestyl libr dexcom longer requir finger stick compani expect
roll multipl advanc continu glucos monitor cgm technolog
ultim remov finger stick calibr requir
possibl question manag
confid next-gener evolut pro tavr devic
launch
level market share eros expect addit competitor
abbott lab launch market
differenti horizon platform evolut platform
latest updat enrol apollo trial expect
transept intrepid devic integr apollo trial
provid addit detail transcathet mitral valv repair
seek expand corevalv evolut indic use low surgic
risk patient popul interim data expect releas american colleg
cardiolog meet march
also continu invest next-gener transcathet aortic valv replac
tavr technolog fiscal expect launch evolut next
gener tavr valv lower profil improv placement also work
new platform name horizon product expand
indic ensur continu double-digit growth tavr busi
also develop transcathet system treat mitral valv octob
receiv fda approv start apollo transcathet mitral valv
replac trial evalu intrepid valv enrol underway site
activ continu work toward incorpor transfemor transept
deliveri tf/t system investor updat meet crt confer march
manag note tf/t first-in-man still month away
suggest us opportun intrepid multipl year away believ
tf/t system like need commerci success
crt investor brief manag convey believ tool box
approach mitral valv diseas like need invest area
transcathet mitral valv repair manag said effort would includ
intern develop effort well potenti activ intern program would
discuss approach due differenti approach want
share detail competitor
possibl question manag
current time launch surgic robot platform
intern market well unit state
view competit landscap surgic robot intuit
surgic entrench competitor j/verili verb surgic also
differenti system other would consid
expect mazor robot spine platform acceler growth
robot surgeri market pioneer intuit surgic today remain
lead robot surgic compani decemb intuit instal base
da vinci surgic system includ europ asia
rest world intuit estim surgeon use technolog
approxim surgic procedur intuit surgic sale
medtron legaci covidien robot surgic platform date back januari
past sever year compani devot signific amount resourc bring
product market timelin system slip compani note delay
work system featur current timelin advanc
system clinic fiscal launch occur fiscal essenti
one year later initi plan
johnson johnson also target market launch verb surgic platform
partnership verili alphabet/googl also recent announc intent
acquir auri health see note purchas auri health commit digital/robot
surgeri click detail increas invest robot surgeri
unit kingdom base cmr surgic recent enter market decemb
launch first train program florida compani versiu system
decemb close acquisit remain stake mazor
billion total gross deal valu billion mazor robot guidanc
system spinal surgeri launch next gener mazor stealth robot
navig platform januari
acquisit expect modestli dilut fiscal adjust ep
given current strength underli busi compani expect absorb
dilut
cardiac rhythm heart failur
possibl question manag
manag long-term view growth rate cardiac rhythm
manag market abil least sustain current market share
larg opportun leadless pacemak
near- long-term outlook heart failur left ventricular
assist devic lvad busi
cardiac rhythm heart failur largest sub-seg within cardiac vascular
group cvg repres total compani sale expect market
grow low-to-mid singl digit next five year though believ well
posit grow busi mid-single-digit rang continu leadership
within atrial fibril diagnost well return core implant busi
growth
receiv fda approv micra leadless pacemak april though last
year first full fiscal year reimburs exit year sale
annual well million revenu product today individu
need single-chamb pacemak estim pacemak popul
howev compani develop next-gener version expand
address market entir pacemak commun micra one-tenth size
tradit pacemak implant via minim invas approach cost tripl
cost tradit pacemak mix benefit signific
target releas micra av end fiscal expand market
applic half market
medtron lvad busi signific pressur quarter owe
competit headwind abbott approv destin therapi well impact
guidelin chang organ transplant weak prompt manag downward
revis expect overal cardiac vascular group growth
possibl question manag
find trial use design on-m
potenti timelin data releas fda approv renal
renal denerv potenti back five year ago signific
enthusiasm around multi-billion dollar market prospect renal denervationth
ablat renal arteri reduc blood pressur level patient hypertens
three major cardiac compani boston scientif st jude renal
denerv program place acquir program million
ardian deal acquir program million
plu mileston million vessix deal market enthusiasm
significantli cool announc januari medtron symplic
trial fail meet primari endpoint went back draw board
attempt anoth shot redesign symplic spyral system latest
european data use symplic spyral system seem encourag though time tell
multi-billion dollar opportun resurrect
novemb began fda-approv clinic trial evalu symplic
spyral renal denerv system patient high blood pressur alreadi
prescrib anti-hypertens medic trial random sham-control
studi random patient center japan europ australia
canada patient follow three year primari safeti endpoint includ
major advers event one month new renal arteri stenosi six month primari
efficaci endpoint ambulatori blood pressur six month subject
prescrib stabl regimen three anti-hypertens medic includ diuret
calcium channel blocker ace/arb inhibitor beta blocker
possibl question manag
outlook brain therapi busi
key new product manag feel could signific
contributor growth
signific could cranial mount db system
medtron brain therapi divis grew constant currenc basi fiscal
growth driven larg success sell capit equip strong
portfolio neurovascular devic also record revenu mazor robot
guidanc system within brain therapi demand stealthstat navig
o-arm imag also driven growth
medtron neurovascular portfolio driven mid-teen high twenti growth sever
year strength attribut solitair platinum stent acut ischem stroke
neuro access product coil intrasaccular therapi well flow divers product
compani expect launch react cathet riptid aspir system
margin return data
balanc sheet cash flow mn
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
overweight believ
number new product across busi
allow sustain mid-single-digit growth
expect leverag provid
least high-single-digit ep growth believ
stock valuat still attract despit recent
appreci share
upsid case driver includ success
deploy market share gain key area
cardiovascular structur heart surgic
neurostimul greater margin expans
expect
inabl receiv product approv market
share loss key categori dilut deal
price pe perform
stryker corp quarterli annual ep usd
consensu number refinitiv receiv gmt
stock outperform broader market past five year compani acceler underli sale growth rate
period
sale product categori
sale geographi
product includ partial total knee implant primari revis procedur cement
cementless product total knee arthroplasti
offer primari revis total hip replac product offer direct superior approach
instrument help spare muscl damag surgeri
trauma extrem product portfolio includ implant bone fractur bone plate bone nail
extrem arthroplasti product biomateri
includ imag system fluid manag product capit sale mako robot surgeri system
product includ power tool accessori surgic navig system wast manag product
endoscopi product includ laparoscop minim invas surgeri imag system along surgic tool
design procedur
includ emerg medic equip hospit patient transport equip intens care
stryker sustain categori includ reprocess remanufactur medic devic
segment includ neurovascular product focus treat stroke patient surgic tool neurosurg spine
ent procedur craniomaxillofaci product
spine product includ spinal implant instrument biomateri navig diagnost tool
well-diversifi compani expect
deliv sale growth overal med-tech market
peer group
abil drive leverag bottom line
stryker underli sale growth could plateau
compani see greater competit orthoped extent
zimmer biomet turn around becom
competit hospit capital-expenditure market also
trend favor trend could soften
like continu success execut
stock trade premium other sector
believ sustain above-sector revenu growth profil see multipl driver across
three busi orthoped medsurg neurotech spine believ deliv
margin commit goal least annual drive least ep growth given
outlook believ premium pe justifi
american academi orthoped surgeon aao host investor
brief
apr societi american gastrointestin endoscop surgeon sage meet
possibl question topic manag
manag current think manag still primarili
focus tuck-in would open larger deal area med-tech
less attract
investor think long-term growth profil compani
recent product launch futur launch import
drive futur growth
confid manag abil drive annual oper
margin improv
view competit environ orthoped
emerg compet robot system zimmer biomet rosa depuy
view sustain rate growth medsurg franchis
trend hospit capital-expenditure market posit
busi within current climat
view sustain rate growth neurotech spine
franchis integr proceed
possibl questions/top manag
possibl question manag
manag current think
manag still primarili focus tuck-in would open larger
area within medic devic view attract
view least
 core growth strategi compani complet
acquisit sinc compani gener look tuck-in style deal addit
product technolog near adjac specif manag note
view neuromodul area interest sever year analyst day novemb
also note interest gener surgeri
 focus continu increas dividend view share
repurchas larg tool off-set dilut
possibl question manag
put take investor consid
investor think long-term growth profil compani
confid manag abil drive oper margin
expans year
organ sale growth rate impress
guid organ growth organ growth fx expect
headwind top line re-affirmed commit drive oper
margin expans despit deal-rel dilut expect ep rang
stryker long-term growth goal includ sale growth high end peer group
least oper margin expans least ep growth background
introduc cost transform program goal achiev
oper margin improv annual period
program first year product recal hurrican damag puerto rico dilut
acquisit novadaq neg impact compani abil achiev
margin expans target oper margin declin adjust
impact headwind achiev oper margin expans
success expand oper margin despit
neg impact
possibl question manag
view zimmer biomet rosa depuy orthotaxi robot
system competit believ system could
inning regard mako penetr
addit area within orthoped believ robot
believ place soft tissu robot platform within
acquir mako surgic corp decemb million repres
ev ltm revenu multipl ev ntm revenu multipl
mako rio robot arm system stryker mako approv partial knee
arthroplasti pka total hip arthroplasti tha time acquisit receiv
clearanc total knee tka applic initi limit launch
march full roll-out occur march
competit environ could becom challeng zimmer biomet plan
limit launch rosa robot platform depuy expect launch
orthotaxi platform
stryker success mako platform total knee arthroplasti provid
compani market growth knee replac strong foundat
build broader orthoped robot platform
next sever year would expect continu build robot
focu hard tissu arena compani novemb investor meet
manag note initi project focus improv shoulder arthroplasti
spine surgeri mako technolog also complet initi homework
appli robot total ankl arthroplasti
regard entri gener surgeri robot manag note
hard tissu near-term focu view gener surgeri logic adjac
possibl question manag
view competit environ hip knee outsid
robot
strategi build upper extrem busi
view shoulder portfolio rel peer forese chang
level invest segment
stryker orthoped segment revenu repres total sale sale
organ basi maintain steadi mid-single-digit high-
single-digit growth larg due market lead growth knee busi well
consist growth trauma extrem unit hip knee market typic
refer larg joint market tend grow low-singl digit trauma
extrem market grow mid-singl digit
decis use cement cementless fixat tka debat sever
decad cement fixat associ high qualiti outcom long-term
follow-up studi osteolysi relat bone stock alter mechan stress due
implant/kne malalign bone/c interfac lead surgeon find new
design flaw plagu earli cementless tka implant nearli tka return cement
fixat osteoconduct surfac fixat technolog improv cementless tka
implant survivorship improv compar cement tka launch
tritanium cementless tibial basepl grown cementless knee
total knee volum cementless tka implant carri higher higher
margin benefit major manufactur cementless tka
market sever year howev zimmer biomet current launch cementless
tibia knee implant depuy johnson johnson plan launch cementless knee
extrem sub-seg steadi double-digit growth engin within
orthoped segment last five year much growth come build
foot ankl busi compani use acquisit memomet
catalyst set dedic foot ankl sale forc continu build
product portfolio intern develop small bone innov
also begun build dedic sale forc upper extrem portfolio
late focus build shoulder offer estim stryker
shoulder market share remain rel low believ catalyst
next leg growth extrem segment
possibl question manag
manag view sustain growth rate medsurg
trend hospit capital-expenditure market
key product launch sustain acceler current rate
growth
near- long-term market opportun novadaq
outlook product
gener plu organ growth medsurg segment last three
year driven intern product innov contribut acquisit
anniversari segment gener million revenu repres
sale sale constant currenc basi organ
endoscopi sub-seg gener million sale repres
constant currenc growth segment growth recent year driven primarili
decemb launch aim surgic video platform next gener
surgic platform expect launch off-set declin sale
acquisit novadaq close septemb also
enhanc sub-seg organ growth profil
complet acquisit product billion april sale
total million consist dispos product focus reduc hospit
acquir condit never event icu medsurg hospit unit set
compani grow low-teen howev compani sever
recal led declin sale juli recal one lot comfort
shield cloth subsequ expand juli receiv warn letter
relat oral solut august initi recal specif lot
oral product put temporari hold cloth-bas product resum
ship octob continu feel impact recal sale declin
year year expect return growth pre-recal level would
expect return take sever quarter play
neurotech spine
possibl question manag
manag see sustain rate growth neurotech
spine market
key new product launch neurotech franchis
rational go deeper spine market via
view neuromodul market logic
adjac expans
gener high single-digit organ growth neurotechnolog spine
segment last three year larg driven strong product innov market
growth within neurotechnolog combin segment gener million revenu
repres total sale segment grew constant currenc
organ look ahead expect continu strong growth driven
neurotechnolog market segment also benefit contribut entellu
neurotechnolog sub-seg gener million sale repres
constant currenc growth much growth neurotechnolog segment
attribut neurovascular product target coil acut
ischem stroke product growth also driven craniomaxillofaci cmf
product neuro power instrument
februari complet acquisit entellu medic purchas
price per share aggreg purchas price million acquisit
expand stryker presenc nose throat ent segment provid
dedic ent sale forc believ entellu franchis sustain growth
high-teen
novemb close acquisit group hold ktwo
per share impli equiti valu approxim billion enterpris valu
approxim billion gener million ltm revenu impli
ev ltm sale multipl consist view spine core busi given
largest orthoped sub-seg meaning overlap neurotechnolog
busi acquisit bolster product portfolio complex spine spine
deform trauma tumor minim invas approach
margin return data
balanc sheet cash flow mn
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
overweight believ sustain
above-sector revenu growth profil see
multipl driver across three busi
believ deliv margin commit
goal least annual drive least
ep growth given outlook believ
premium pe justifi
growth greater success new product
greater success drive oper margin
downsid case driver includ slowdown
orthoped hospit capital-expenditure market increas
competit knee foreign exchang stronger
us dollar inabl drive margin expans
price pe perform
quarterli annual ep usd
consensu number refinitiv receiv gmt
januari benson smith appoint ceo share risen sinc result improv sale trend margin
success execut number transact restructur initi soft earn report downward earn
revis guidanc caus sell end though compani decemb announc vascular solut
acquisit expect sale cost synerig improv organ trend drove share higher stock trade higher prospect
acceler top-line growth septemb announc neotract acquisit share remain rel rang bound
sever distributor hiccup question around growth base busi off-set upsid potenti neotract
sale product categori
sale geographi
product includ cathet relat devic posit use intraven medic administr blood
pressur measur draw blood sampl product primarili market arrow brand name
teleflex anesthesia segment includ pain airway manag product pain product includ epidur kit
peripher nerv block kit dispos pain pump airway manag product includ mask atom
devic endotrach tube laryngoscop
divis includ product use intervent cardiologist intervent radiologist vascular surgeon
cathet devic treat coronari peripher vascular diseas bone marrow access system
hemodialysi cathet cardiac diagnost cathet includ busi segment
product includ singl use reusabl product ligat wound closur system
laparoscop surgic instrument port
increas compani urolift franchis
categori includ single-us respiratori urolog
view result mix headlin number suggest sale
slightli street organ sale growth much growth
come urolift vsi legaci growth ep beat function
lower tax rate oper margins/incom expect
guidanc larg bracket street weight back-half overal
view unchang outlook heavili depend continu success past
million except per share data chang sale constant currenc organ basi unless otherwis note
addit detail quarter
addit takeaway confer call
pleas see note click kstew call note
modest clear focu urolift date
urolift strength continu sale increas y/i contribut
overal growth y/i full year clinic result
continu posit
vascular solut vsi sale increas y/i reflect strong growth
north america emea benefit distributor convers
management announc anoth restructur program expect plan-rel save
begin reach annual pre-tax save plan fulli
implement action expect substanti complet
organ sale growth net ship day quarter increment
urolift sale contribut increment vsi sale contribut thu
base busi grew around exclud surgic exit
ep beat estim sale ahead oper margin came
lower vs estimate result lower oper profit dollar
quarter delta estim beat function lower tax
rate benefit rel estim lower interest expens
midpoint commentari impli street impli sale
vs street ep vs street
sale report constant currenc organ basi
result benefit addit sell day ad
gross margin y/i reflect effici higher urolift
intervent access sale volum benefit distributor buy-in fx
sg sale y/i
 sale bp y/i
oper margin y/i reflect increas gross margin
offset effect sg
adjust tax rate vs prior year expect
adjust ep street estimate estimate
manag expect report revenu base full year revenu growth guidanc impli
revenu ep expect full year impli quarter manag anticip major
full year fx headwind occur bulk
expect report sale growth constant currenc sale growth guidanc compani project gross
margin expans oper margin expans interest expens tax rate rang
net/net result expect ep bracket street pre-result
guidanc could prove conserv given
perform urolift potenti revenu new
product manta percuv repla
legaci busi deceler grew
extent perform improv could
present risk achiev long-rang forecast
achiev beat long-rang plan goal
revenu growth oper margin
stock current trade premium med-tech
name reflect expect high growth
believ neotract vsi acquisit help sale growth prospect howev core
growth rate struggl improv howev ep estim street
believ fx rise interest rate headwind given believ stock fairli valu
apr societi american gastrointestin endoscop surgeon sage meet
may american urolog associ aua meet relev urolift
possibl question topic manag
put take investor consid
investor think long-term growth profil compani
manag confid long rang plan lrp outlin may
confid abil legaci ex-vascular solut neotract
sale growth lrp period
confid abil achiev long-rang plan margin target could addit
invest need achiev target top line growth
expect tuck-in deal could anoth larger transact also like essenti
futur sustain growth
view market opportun urolift view competit
landscap sustain favor reimburs profil product
view sustain growth profil vascular solut busi
key pipelin product could help drive better expect top-lin growth
view potenti futur contribut manta vascular closur product repla
percuv couldnt signific driver near-term outlook
possibl questions/top manag
possibl question manag
put take investor consid could new
product contribut percuv manta drive upsid
investor think long-term growth profil compani
manag confid long rang plan lrp outlin may
confid abil legaci ex-vascular
solut neotract sale growth lrp period
confid abil achiev long-rang plan margin
target could addit invest need achiev target top line
revenu increas report basi constant
currenc basi acquisit ad overal growth thu organ sale
growth estim legaci busi ex-vsi neotract
grew adjust exit surgic product line thu delta
repres increment contribut anniversari vsi neotract
vsi neotract includ result pro forma basi report
basi growth estim constant currenc basi
expect constant currenc revenu growth expect
gross margin oper margin adjust ep
expect rang
may outlin long-rang plan lrp next three year
period expect averag organ constant currenc revenu growth
rate assum base busi grow rate vascular
solut acquisit add growth neotract add lrp
expect adjust gross margin continu expand
oper margin expand
actual adjust
possibl question manag
manag ideal leverag posit
expect tuck-in deal could anoth larger transact also
like essenti futur sustain growth
recent year gener reli tuck-in acquisit drive top-lin growth
made two larg platform acquisitionsvascular solut neotract
may investor day note intend remain serial acquir
focu invest key diseas state market decemb
compani million cash million debt leverag ratio
possibl question manag
view market opportun urolift
urolift compar boston scientif rezum term efficaci
urolift reimburs compar avail therapi
urolift minim invas technolog treat lower urinari tract symptom due
benign prostat hyperplasia bph urolift expect contribut per
year long-rang plan octob complet acquisit
neotract develop urolift system million up-front payment plu
million conting mileston
urolift intervent urolog sale million increas
million level next five year believ urolift sale could grow
million driven continu adopt aid recent inclus urolift
standard care option treatment enlarg prostat american urolog
associ aua clinic guidelin address patient popul larg
incid bph men men
men age us alon million men treat bph though
initi focu us opportun intern opportun equal larg
sale primarili uk though work reimburs
countri also receiv shonin japanes approv though await
reimburs fulli launch product worth note mileston
pay-out million base sale target million
risk forecast could competit minim invas bph market could becom
competit boston scientif rezum system rezum
fundament differ urolift urolift procedur perman implant place
hold open obstruct pathway block urin flow minim
invas transurethr outpati procedur rezum use water vapor remov excess
prostat tissu allevi obstruct flow rezum clear fda though
uptak rezum thu far limit reimburs
possibl question manag
key pipelin product could help deliv top-lin growth
discuss rational acquisit manta vascular closur
devic essenti medic expect contribut go forward
view market opportun repla
re-launch strategi percuv still believ
manag goal acceler compani organ sale growth rate
higher mani year period organ sale growth averag
estim legaci busi ex-vsi neotract deceler
growth ex-th surgic exit estim
compani develop acquir sever product besid neotract vsi
offer potenti drive improv sale growth
octob acquir essenti medic million million
potenti sale regulatori mileston payment essenti medic develop manta
vascular closur devic design closur larg bore arteriotomi typic associ
transcathet aortic valv replac tavr endovascular aneurysm repair
evar devic receiv ce mark approv juli follow patient
sec median sec low complic rate
februari manta vcd system receiv fda approv follow
manta trial trial singl arm patient trial primari endpoint focus
time hemostasi manag note believ tavr evar opportun
million approv come earlier expect
timelin compani continu expect initi limit market releas ensur
strong clinic outcom manag expect signific amount manta
revenu
comparison across clinic trial tricki result previou trial compar
current larg bore vascular closur devic provid potenti opportun manta take
share view assum result fda studi line ce mark studi
abbott perclos proglid indic use access site femor arteri
use sheath access site femor vein use sheath
current primari vcd market larg bore arteriotomi perclos
proglid similar safeti data major complic rate mean time hemostasi
minut second patient requir secondari closur method
manual compress subcutan stitch requir two proglid sutur
acquir repla part acquisit vascular solut product
develop armi armi sponsor clinic trial treatment
battlefield trauma emerg applic retain commerci
right repla
resuscit plasma requir stop uncontrol bleed prevent shock
compani estim civilian trauma patient militari patient
requir massiv transfus due hemorrhag
current civilian plasma stock typic store frozen requir minut thaw
thaw maintain shelf life dynam coupl urgenc associ
trauma case lead plasma wast approxim expect
civilian opportun sell em transport hospit segment
although view immedi opportun servic militari market
militari current freeze-dri plasma avail howev glass bottl
fragil militari medic transport repla packag freez dri plasma polym bag
store room temperatur reconstitut steril water two minut
estim total market size repla approxim million
govern contract repres roughli million civilian use remain
million product receiv acceler bla approv pathway april
recent complet phase safeti trial expect submit final modul
bla submiss approv repla could potenti upsid driver teleflex
forecast compani note includ modest sale repla lrp
given bla submiss timelin would expect fda approv
percuv surgic system percutan approach access inner organ
tissu achiev via needl punctur laparoscop surgeri percutan
approach reduc number trocar medic devic function portal
subsequ placement instrument provid better angl surgeon
address surgic site minim trauma patient develop percuv
intern receiv initi fda ce mark approv product launch
protract manag initi thought addit fda trial
issu voluntari recal multipl delay push return product
manag assum immateri amount percuv revenu past
manag comment percuv could million opportun
continu grow modestli deceler
success past deal notabl
neotract urolift vsi help acceler
overal growth believ sale growth
achiev warrant premium pe
stock current reflect equal weight
upsid case could driven greater urolift
vsi sale greater improv profit
improv core busi sale growth
rate accret
downsid case could driven slowdown
urolift sale rel expect challeng
within core busi foreign exchang rate
stronger us dollar higher interest rate
margin return data
balanc sheet cash flow mn
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
quarterli annual ep usd
consensu number refinitiv receiv gmt
price pe perform
share trade roughli past five year compani struggl growth outlook zimmer
announc intent acquir rival biomet april initi enthusiasm around prospect combin entiti
howev compani experienc deceler sale growth trend head deal close june earli
renew enthusiasm potenti acceler growth howev prove fleet stock struggl
financi outlook remain lacklust compani announc challeng manufactur qualiti front fda decemb
zimmer biomet announc bryan hanson would next ceo intial enthusiam around appoint though
lower earn reset prompt declin stock price view recent move upward hope earn outlook
final reset new manag team lead compani transform growth
sale product categori
sale geographi
zimmer biomet knee implant portfolio includ product instrument primari revis procedur
compani offer partial knee system total knee system person implant solut market
segment includ hip arthroplasti implant instrument primari revis procedur
sport extrem
product includ soft tissu injuri repair product sport medicin patient extrem repair replac
devic like plate bone nail shoulder elbow implant biolog solut enhanc recoveri
trauma surgeri
dental product includ dental implant system surgic kit surgic tool regen product
includ spinal implant devic design treat traumat injuri degen condit biolog solut
electron stimul product within spine divis cmf divis includ facial skull
reconstruct product product bone fixat stabil chest injuri cardiac surgeri
segment includ bone cement offic base technolog product like zimmer biomet spinalpak spinal fusion
zimmer biomet new manag team success
overse transit back least market growth
 could shift portfolio higher wamgr
knee rosa robot lead improv
underli growth knee busi zb largest
stock inexpens adjust pe basi
zb continu deal outstand fda warn letter
remedi effort could continu prove costli
zb still somewhat lever balanc sheet cash
flow still reflect on-going remedi special
abil expand margin could limit need
reinvest back busi drive futur growth
view appoint bryan hanson ceo posit catalyst chang believ
orchestr turnaround howev believ transform need like take multipl
year sever new product could help competit posit knee impact like
materi also see ep risk
american academi orthoped surgeon aao zimmer biomet host
investor event
possibl question topic manag
investor think long-term growth profil compani gross
oper margin go time action compani take achiev
current statu remedi effort impact suppli level
recent product launch futur launch import drive
expect roll-out rosa robot platform unfold
view long term strategi within dental spine busi
manag current think abil transform portfolio
manag view attract target extent would compani
will transact white space diversifi revenu profil rather
tuck-in deal adjac core portfolio today
possibl questions/top manag
possibl question manag
put take investor consid
investor think long-term growth profil compani
gross oper margin go time action
compani take achiev margin goal
put take behind achiev wamgr
zimmer biomet challeng year one year transit
zimmer biomet currenc revenu growth reflect increas
volume/mix off-set neg price rate growth overal
orthoped market oper margin finish year
prior year reflect lower gross margin higher level sg spend
adjust cash ep compar prior year
januari manag provid guidanc expect sale growth flat plu
minu includ estim bp headwind fx manag
expect weaker due one fewer bill day absorb virtual
neg fx impact year manag expect oper margin
rang tax rate ep
zimmer expect achiev growth weight averag market growth rate
wamgr
possibl question manag
statu remedi effort warsaw campu
outcom regulatori meet fda
back suffici suppli level product
statu two warn letter canadian puerto rico
much spend need resolv warn letter address
manufactur defici across compani
could compani risk corpor warn letter
late fda inspect zimmer biomet north campu manufactur facil
warsaw indiana issu fda inspect observ
inspect observ issu conclus inspect fda
investig observ condit may constitut violat food drug
cosmet fd act relat act april zimmer receiv anoth
relat north campu facil subsequ respond fda august
zimmer biomet receiv warn letter fda relat north campu facil
warn letter fda acknowledg progress made zimmer biomet
note outstand defici fda also propos regulatori meet discuss
propos correct
manufactur qualiti remedi effort initi affect zimmer biomet abil
produc adequ suppli product across knee hip busi unit
compani work improv suppli product made progress eas
constraint earn call manag note qualiti
remedi plan complet plant readi re-inspect
end compani product suppli situat continu improv
north campu facil warn letter face compani may
zimmer biomet receiv warn letter fda relat observ non-conform
current good manufactur practic requir qsr facil montreal
canada septemb legaci zimmer receiv warn letter fda cite
concern relat certain process pertain product manufactur ponc
puerto rico manufactur facil warn letter remain outstand
possibl question manag
manag strategi roll-out rosa robot platform total knee
compani plan market rosa robot rel stryker mako
smith nephew navio system consid key featur
rosa
sort up-tak investor expect term capital/robot
placement time well potenti pull-through benefit implant
zimmer biomet acquir rosa robot system juli acquisit
med-tech sa french med-tech compani origin applic rosa spine
compani iter platform use total knee arthroplasti januari
zimmer receiv fda approv total knee applic expect zimmer biomet
market product upcom aao meet though fuller launch expect
possibl question manag
dental core part compani spine
appropri leverag level zimmer biomet posit
conduct
extent would compani will transact would
adjac white space diversifi revenu profil
capit alloc like critic longer term success zimmer biomet share
believ mr hanson look increas compani weight faster end market
manag note desir diversifi growth engin like categori
within sport extrem trauma set march wall street journal report
zimmer biomet retain advisor assess potenti divest
compani dental busi zimmer biomet hold consid sale dental
manag comment merit report
strategi activ portfolio manag uniqu med-tech success
compani strategi acquir compani potenti acceler
underli sale growth rate acquir cost-sav synergi think
med-tech landscap compani consid aggress activ portfolio
manag includ baxter avano formerli halyard health differ
compani zimmer biomet balanc sheet decemb zimmer
biomet net debt billion compani expect gener billion
free cash flow gener billion small amount earmark
pay dividend million think much balanc year like go
pay debt net debt ebitda close decemb
zimmer biomet may look use cash flow purpos
margin return data
balanc sheet cash flow mn
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
underweight view appoint
bryan hanson ceo posit catalyst chang
believ orchestr turnaround
howev believ transform need
like take multipl year sever new product
could help competit posit knee
impact like materi also
upsid case could driven improv
market trend orthoped greater success
improv price trend strateg
downsid case could driven inabl
receiv and/or execut new product approv
deterior price addit fda regulatori
exchang stronger us dollar dilut
pleas note background inform contain within appendix factual includ due compani attend
barclay healthcar confer
le maitr vascular merit medic system tandem diabet coverag barclay research
inform compani provid inform purpos invest recommend
barclay research
price consensu estim valuat
price ev/sal perform
angiodynam inc cover price sale ep estimatesfor fiscal year end cap mil epsev/salesenterpris val price metric consensu angiodynam hc eq barclay medic suppli devic
sale product categori fy
sale geographi fy
product includ fluid inject manag visual kit solut product includ
angiovac minim invas venou drainag system remov occurr thrombosi embol
vascular access divis includ product design cathet placement usag procedur like
hemodialysi ultrasound product cathet packag port packag includ segment
ablat system radio-frequ thermal ablat product assist tumor resect sold
within oncology/surg divis nanoknif major product within divis also includ
product biosentri radiadyn acquisit
angiodynam framework growth per investor present januari
angiodynam manag highlight two area framework growth
deliv sustain improv margin
focu invest growth innov
continu commit qualiti complianc
focu area compel unmet need patient-centric/evidence-bas
increas focu high-growth market
price consensu estim valuat
price ev/sal perform
inc cover price sale ep estimatesfor fiscal year end cap mil epsev/salesenterpris val price metric consensu hc eq barclay medic suppli devic
product creat process decellular human peripher nerv tissu use
allograft repair peripher nerv injuri process use creat product maintain extracellular
matrix ecm allow nerv fiber regener structur heal sever nerv
avanc sold length diamet repres revenu
aviv soft tissu membran use minim inflamm separ tissu peripher
nerv repair surgic bed product made human umbil cord membran process
steril
axoguard nerv protector
nerv protector made process decellular porcin ecm product wrap
around damag peripher nerv use reinforc repair protect nerv attach
surround soft tissu
nerv connector also made process decellular porcin ecm product hollow
tube shape use reinforc peripher nerv repair site bridg gap nerv
end less apart
axoguard product sold exclus distribut agreement cook biotech
run june
acrov neurosensori motor
acrov digit system use evalu sensori motor function peripher nerv condit like
neuropathi nerv compress transect nerv product launch march
compos acrogrip hand grip strength measur acropinch pinch strength pressure-
specifi sensori devic evalu measur pressur sensit
axotouch point discrimin tool made measur peripher nerv sensori function test innerv densiti surfac
skin devic consist two aluminum disc contain set prong around perimet
prong differ distanc apart one anoth mostli rang apart
financi guidanc per compani februari earn press releas
manag expect follow
total revenu rang million larg driven new sale repres hire
gross margin expect remain
compani plan hire direct sale repres bring year-end total around
price consensu estim valuat
price ev/sal perform
axon modul technolog inc cover price sale ep estimatesfor fiscal year end cap mil epsev/salesenterpris val price est valuat metric barclay medic suppli devic
axon r-snm implant recharg sacral nerv modul snm devic devic design
low profil first recharg snm design replac everi year compar
year replac cycl medtron interstim system
r-snm system market approv europ canada australia treatment treat patient
overact bladder oab fecal incontin fi urinari retent ur februari
compani receiv ce mark approv mri full-bodi condit label
decemb axon submit literature-bas pma applic fda overact bladder
oab urinari retent ur sinc compani submit variou amend
includ data support condit full-bodi mri label along complet
clinic data artisan-snm studi march compani submit new literature-bas
pma seek approv fecal incontin fi axon anticip fda approv late
sacral nerv control pelvic function sacral nerv modul mild electr puls
demonstr reduc bowel void leak
axon believ r-snm system potenti disrupt grow estim million global
snm market countri control singl particip estim market
million american suffer combin two dysfunct significantli
neg impact patient qualiti life emot well-b especi tandem
price consensu estim valuat
price ev/sal perform
cardiovascular system inc cover price sale ep estimatesfor fiscal year end cap mil epsev/salesenterpris val price metric consensu est barclay medic suppli devic
sale product categori
csi main product diamondback orbit atherectomi system
peripher system origin clear fda august commerci launch septemb
devic remov plaqu lesion knee devic often use vessel
prepar allow low pressur percutan translumin angioplasti pta includ use drug-coat
coronari system approv fda octob devic use prepar vessel treat
sever calcium prior help facilit vessel access stent expans
system use low-profil cathet travel viperwir guid wire electr power
small portabl salin infus pump cool system remov debri cathet includ electrically-
power control handl allow movement crown flexibl drive shaft eccentr mount
diamond-co crown track orbit guid wire sheath cover drive shaft
permit deliveri salin medic treatment area
compani strategi
csii goal lead provid solut treatment peripher arteri diseas pad coronari arteri diseas cad csi
intend broaden product offer expand intern market strategi includ follow
drive adopt direct sale organ medic educ opinion leader
build strong portfolio clinic evid safeti effect econom benefit
enhanc expand product portfolio within market treatment peripher coronari arteri
price consensu estim valuat
price pe perform
cooper compani inc cover price sale ep estimatesfor fiscal year end cap mil epsev/salesenterpris val price metric consensu est barclay medic suppli devic
sale product categori
sale geographi
toru shape surfac instead tradit spheric surfac avail myday clariti
day biofin avaira vital product line
brand name includ biofin monthli lens clariti day dispos lens
product line includ myday clariti day offer day dispos spheric lens
non-singl use
sold biofin brand name last month worn consecut day avaira
vital last week
product includ medic devic use women healthcar provid varieti medic set offer
includ surgic tool offic devic labor deliveri neonat critic care product paragard intrauterin
contracept devic major brand segment acquir
genet test kit correspond equip along vitro fertil equip kit part
divis includ correspond instrument devic need complet genet
test vitro fertil patient
financi guidanc per compani march earn press releas
manag expect follow
total revenu million pro forma
revenu million pro forma
csi revenu million pro forma
non-gaap dilut earn per share
price consensu estim valuat
price ev/sal perform
insulet corp cover price sale ep estimatesfor fiscal year end cap mil epsev/salesenterpris val price metric consensu est barclay medic suppli devic
sale product categori
continu insulin deliveri system includ pod person diabet manag pod
provid three day non-stop insulin deliveri worn multipl locat includ
abdomen hip back upper arm thigh lower back also waterproof
next-gener omnipod system featur secur bluetooth-en pod
touch screen color user interfac support smartphon connect incorpor secur featur
bluetooth function also provid connect smartphon app june fda clear
product commerci distribut us initi limit commerci releas
expect full market launch
system develop hybrid close loop control system util dash mobil
platform allow pod commun continu blood glucos sensor help control
insulin deliveri use algorithm locat pod system intend control
secur mobil app smart phone system grant design fda breakthrough devic
develop new product collabor leverag dash mobil platform
support use concentr insulin type type patient product design
deliv units/ml humulin insulin concentr form insulin use
highli insulin resist type diabet
partner pharmaceut biotechnolog compani tailor omnipod system
deliveri subcutan drug major drug deliveri revenu sale pod
compani strategi
sell omnipod directli patient intermediari independ distributor pharmaci channel
unit state canada europ israel
year end decemb approxim us omnipod sale intermediari cover
omnipod system medicar part prescript drug benefit expand access pharmaci
channel believ provid sever competit advanc durabl medic equip dme distribut use
along result provid guidanc includ
revenu rang million repres revenu growth includ
 omnipod revenu million increas
intern omnipod revenu million increas
drug deliveri revenu million decreas
price consensu estim valuat
price ev/sal perform
 cover price sale ep estimatesfor fiscal year end cap mil epsev/salesenterpris val price metric consensu est barclay medic suppli devic
sale product categori
sale geographi
divis includ cathet sheath along product develop manufactur servic
diagnost intervent cardiac endovascular devic
product line offer includ puls gener lead compon implant cardiac
neuromodul devic along manufactur design servic
segment includ orthoped implant correspond instrument electro surgic equip
accessori batteri pack medic devic provid custom manufactur servic
divis includ custom power solut non-med applic includ batteri cell batteri
pack batteri charger product design energi militari environment market
must reliabl abl withstand extrem condit
along result manag provid follow guidanc
sale million report non-gaap basi
non-gaap incom million increas y/i
non-gaap ebitda million y/i
non-gaap ep increas y/i
manag comment plan execut product line strategi drive oper strateg imper look bolt
acquisit disciplin capit deploy
manag also indic strateg object includ
grow revenu market
drive profit growth revenu growth
debt leverag
price consensu estim valuat
price ev/sal perform
 cover price sale ep estimatesfor fiscal year end cap mil epsev/salesenterpris val price metric consensu est barclay medic suppli devic
sale geographi
peripher vascular product busi sell devic offer tissu process preserv servic treat vascular diseas
carotid shunt vascutap radiopaqu tape
broad product categori includ scope visual system cathet well patch vascular
recent acquisit per compani februari earn press releas
septemb lemaitr acquir appli medic embolectomi cathet busi million acquir busi
includ syntel embolectomi cathet python over-the-wir embolectomi cathet lati graft clean cathet sale
acquir busi prior acquisit million lemaitr believ second largest
provid embolectomi cathet world-wide
octob lemaitr acquir asset cardial subsidiari becton dickinson total purchas price
million cardial base st etienn franc product line includ vascular graft valvulotom surgic glue sale
acquir busi prior acquisit million concentr mostli europ
compani strategi
lemaitr releas result provid guidanc februari manag expect
sale million mid-point repres sale growth report basi organ
gross margin
oper incom million midpoint ex-speci item
ep midpoint ex-speci item
price consensu estim valuat
price ev/sal perform
masimo corp cover price sale ep estimatesfor fiscal year end cap mil epsev/salesenterpris val price metric consensu est barclay medic suppli devic
annual revenu million
product sale geographi
accord set design overcom primari limit convent puls
oximetri maintain accuraci presenc motion artifact low perfus weak signal-to-nois
situat masmio set util five signal process algorithm four proprietari complement
set platform compani develop single-us reusabl sensor cabl
leverag set technolog incorpor licens rainbow technolog allow real-tim
monitor addit non-invas measur measur avail includ sphb hemoglobin
spoc oxygen hemoglobin spco carbon monoxid spmet methemoglobin pvi pi chang
fraction oxygen satur oxygen statu moder hyperox rang
measur brain electr activ detect eeg signal process display singl number
call patient state psi give continu quantit indic patient depth
anesthesia sedat also display raw eeg waveform psi trend densiti spectral array view
product abil measur multipl expir gase carbon dioxid oxid
oxygen anesthet agent
also known tissu cerebr oximetri use near-infrar spectroscopi nir provid continu
measur tissu oxygen
root patient monitor connect platform integr rainbow set measur
multipl addit specialti measur open architectur technolog integr
compani strategi
strategi includ follow element
continu expand market share puls oximetri note revenu compound-annual-growth-rate attribut
growth continu expans core set puls oximetri custom base higher revenu rainbow puls co-oximetri
nomolin capnographi new technolog well expand list oem partner
expand puls oximetri market patient care set believ abil broaden outsid
critic care set includ gener medic surgic floor hospit
expand use rainbow technolog hospit set believ non-invasive measur rainbow puls
co-oximetri sphb spco spmet spoc rainbow acoust monitor rra
well futur measur provid opportun help custom improv patient care reduc overal cost
care
expand use rainbow technolog non-hospit set would includ physician offic emerg depart
blood donat center fire/altern care market
expand use root hospit set
util custom base oem relationship market rainbow set sedlin capnographi product incorpor
continu innov maintain technolog leadership posit
provid full year financi guidanc februari earn call compani expect
product revenu growth constant currenc basi
gross margin y/i exclud royalti nre revenu
sg expens percent sale y/i exclud royalti nre revenu
 sale y/i even prior year exclud royalti nre revenu
oper margin
non-gaap product oper margin exclud impact royalti nre
dilut ep
non-gaap ep repres increas y/i exclud royalti nre revenu
long term plan includ follow financi target
revenu growth
gross margin
oper expens
oper margin
leverag oper structur improv tax rate time
present januari manag cite revenu growth opportun
set growth continu larg share puls oximetri market still avail gener floor expans
rainbow expans opportun includ partnership larg oem
price consensu estim valuat
price ev/sal perform
 cover price sale ep estimatesfor fiscal year end cap mil epsev/salesenterpris val price metric consensu est barclay medic suppli devic
sale product categori
note us sale account total sale
includ access angiographi intervent drainag biopsi solut
includ varieti product treat variou heart condit includ product portfolio area
access angiographi hemostasi intervent electrophysiolog cardiac rhythm manag
cardiovascular critic product treat patient life-threaten diseas protect healthcar worker exposur
bloodborn pathogen provid medic devic design effici effect product
includ dualcap disinfect protect system medallion syring sharp holder product
monitor devic fluid manag devic
product portfolio includ deliveri system embolotherapi spine ablat vertebr compress
cianna acquir novemb acquisit merit began sell savi
brachytherapi breast radiat savi scout radar local
product gastrointestin pulmonari condit
specialti procedur product coat servic medic tube wire origin equip manufactur oem brand
financi guidanc per compani februari earn press releas
manag expect follow
net sale million includ core revenu growth
adjust non-gaap gross margin
effect tax rate
non-gaap ep
manag comment expect
revenu growth
gross margin expans
net incom improv
price consensu estim valuat
price ev/sal perform
 cover price sale ep estimatesfor fiscal year end cap mil epsev/salesenterpris val price metric consensu est barclay medic suppli devic
sale product categori
tandem flagship pump platform pump high-resolut color touchscreen shatter-
resist glass aluminum case recharg batteri slim compat tandem
devic updat tool allow pump user updat pump softwar person
comput allow custom abil new featur continu glucos monitor
integr basal-iq technolog without buy new devic typic four-year
slim basal-iq technolog slim basal-iq technolog receiv fda approv june tandem launch product
unit state august first insulin pump receiv approv integr
continu glucos monitor icgm compat also compani first gener
autom insulin deliveri aid algorithm system use dexcom sensor valu temporarili
suspend insulin deliveri help minim frequenc and/or durat hypoglycem event
lock infus set
slim control iq technolog
septemb tandem began replac standard luer-lock connector join infus set
cartridg custom connector lock lock offer reduc time fill tube amount
insulin use process also reduc possibl air bubbl trap transit result
increas infus set sale
system develop second-gener aid expect integr technolog
licens typezero dexcom cgm sensor icgm design provid
opportun integr develop effort futur icgm sensor new algorithm intend
increas decreas basal insulin base predict blood glucos level deliveri autom
next-gener hardwar platform develop system design half
size slim expect featur unit cartridg on-pump bolu button recharg
batteri aid algorithm bluetooth radio tandem anticip pursu fda author ace
pump design compat aid algorithm avail icgm tandem
goal receiv fda author unit state thereaft submit approv
compani strategi
drive domest adopt product sale market clinic infrastructur
drive adopt product intern canadian sale custom support infrastructur distribut
promot awar product consum caregiv healthcar provid
advanc clinic activ demonstr use pump product may contribut improv clinic outcom
continu innov provid product address unmet need peopl insulin-depend diabet market
invest consumer-focus approach
broaden direct access third-parti payor reimburs product unit state
leverag manufactur oper achiev cost product effici
balanc liquid
decemb tandem million cash cash equival short-term invest
guidanc per compani press releas februari
tandem manag team expect follow
total sale million increas prior year
sale approxim million
gross margin approxim
adjust ebitda break-even
non-cash charg includ cog oper expens million million stock-bas comp million
kristen stewart cfa herebi certifi view express research report accur reflect person view
subject secur issuer refer research report part compens directli indirectli relat
specif recommend view express research report
